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Lentiviral Integration Site Targeting: Host Determinants and Consequences
Abstract
A necessary step in the retroviral lifecycle is integration, the covalent insertion of the viral cDNA into the
genome of the infected cell. This means that retroviruses, for example HIV, establish life-long infection. It
also means that retroviruses are used as gene-delivery vectors to treat genetic diseases. Integration
events are distributed non-randomly in the genome of the infected cell, with characteristic genus-specific
preferences. In this dissertation, we focus on the lentiviral class of retroviruses, and explore two aspects
of their integration: the means by which integration is targeted to its favored sites, and the consequences
of integration at these sites for the host cell. The host protein LEDGF/p75 has been shown to interact with
lentiviral integrases and contribute to their preference for integration in genes. We sought to establish the
extent to which integration site selection is determined by LEDGF/p75 tethering. We first asked whether
LEDGF/p75 was an essential integration tether, by analyzing integration site distribution in cells
stringently depleted for LEDGF/p75. We found that LEDGF/p75 is responsible for much of the lentiviral
integration preference, though probably not all. Secondly, we asked whether LEDGF/p75 tethering is
sufficient to determine the genomic distribution of lentiviral integration. We used a fusion of LEDGF/p75’s
integrase-binding domain and the heterochromatin-binding protein CBX1 to show that lentiviral integration
could be retargeted away from its usual distribution and into CBX1-bound regions. These results
underline LEDGF/p75’s central role in lentiviral integration, and the potential for manipulating its
interaction with integrase. The effect of retroviral integration on the host cell is of particular relevance in
gene therapy, where insertional activation of proto-oncogenes in patients is a serious concern. We
present data on the genomic integration site distribution of a lentiviral vector for the correction of βthalassemia in mice. While use of the same vector in a human patient led to clonal outgrowth, we report
no evidence of insertional activation in the mouse model, but instead the suggestion that integration in
genes may impart a growth disadvantage. This argues for the safety of lentiviral vectors, but raises
questions about their effect on host gene expression.
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ABSTRACT

LENTIVIRAL INTEGRATION SITE TARGETING: HOST DETERMINANTS
AND CONSEQUENCES
Keshet Ronen
Advisor: Frederic D. Bushman

A necessary step in the retroviral lifecycle is integration, the covalent insertion
of the viral cDNA into the genome of the infected cell. This means that retroviruses,
for example HIV, establish life-long infection. It also means that retroviruses are
used as gene-delivery vectors to treat genetic diseases. Integration events are
distributed non-randomly in the genome of the infected cell, with characteristic
genus-specific preferences. This dissertation focuses on the lentiviral class of
retroviruses, and explores two aspects of their integration: the means by which
integration is targeted to its favored sites, and the consequences of integration at these
sites for the host cell. The host protein LEDGF/p75 has been shown to interact with
lentiviral integrases and contribute to their preference for integration in genes. We
sought to establish the extent to which integration site selection is determined by
LEDGF/p75 tethering. We first asked whether LEDGF/p75 was an essential
integration tether, by analyzing integration site distribution in cells stringently
depleted for LEDGF/p75. We found that LEDGF/p75 is responsible for much of the
lentiviral integration preference, though probably not all. Secondly, we asked

v

whether LEDGF/p75 tethering is sufficient to determine the genomic distribution of
lentiviral integration. We used a fusion of LEDGF/p75’s integrase-binding domain
and the heterochromatin-binding protein CBX1 to show that lentiviral integration
could be retargeted away from its usual distribution and into CBX1-bound regions.
These results underline LEDGF/p75’s central role in lentiviral integration, and the
potential for manipulating its interaction with integrase. The effect of retroviral
integration on the host cell is of particular relevance in gene therapy, where
insertional activation of proto-oncogenes in patients is a serious concern. We present
data on the genomic integration site distribution of a lentiviral vector for the
correction of β-thalassemia in mice. While use of the same vector in a human patient
led to clonal outgrowth, we report no evidence of insertional activation in the mouse
model, but instead the suggestion that integration in genes may impart a growth
disadvantage. This argues for the safety of lentiviral vectors, but raises questions
about their effect on host gene expression.
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CHAPTER 1 – INTRODUCTION

1.1 Properties and lifecycle of the Retroviridae
Retroviruses are a diverse class of spherical, enveloped RNA viruses
belonging to the family Retroviridae. Retroviral virions are 80-150nm in diameter
and composed of two copies of a single-stranded positive-sense RNA genome,
surrounded by a protein core, enveloped in a lipid bilayer of host cell origin studded
with viral glycoproteins. Two steps in the viral lifecycle define the group: reverse
transcription of the single-stranded RNA genome into double-stranded DNA, and
subsequent integration of this DNA copy of the genome into the genome of the
infected cell.
A schematic of the virion structure and lifecycle of retroviruses is illustrated
in Figure 1-1. Following interaction of viral envelope proteins with a cellular
receptor, membrane fusion takes place, either at the surface of the host cell or after
endocytosis, depending on the retrovirus [1-4] and the viral core is released into the
cytoplasm [5]. The core is made up of, in addition to the RNA genome dimer, the
structural proteins matrix (MA), capsid (CA) and nucleocapsid (NC), and the
replication enzymes protease (PR), reverse transcriptase (RT) and integrase (IN).
Accessory proteins may also be present depending on the virus, as well as other
molecules from the host cell [6-8]. After entry, the core undergoes a poorly
characterized change in core composition known as uncoating [9]. Reverse
transcription, mediated by virion-packaged RT, takes place [10] and the core moves
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Figure 1-1. The retroviral lifecycle. A. A retroviral particle. B. The retroviral
lifecycle. Adapted from Greene and Peterlin [9].
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through the cytoplasm to the nucleus by interactions with actin microfilaments [11]
and microtubules [12]. Further changes in core structure following reverse
transcription generate the pre-integration complex (PIC), made up of the reverse
transcribed genome, associated with a number of viral and cellular proteins [10, 1315]. When the PIC reaches the host chromatin, the viral cDNA is integrated into the
host genome by IN [16-20]. Integrated viral genomes, known as proviruses, then
function akin to endogenous host genes, transcribed and translated by host machinery
to generate new viral RNA genomes and virion proteins.
The genomes of retroviruses contain four essential genes encoding virion
proteins: Gag, Pol, Pro and Env. Pro (PR) is the viral protease, and posttranslationally cleaves polyproteins Gag and Pol during virion maturation. Gag is
cleaved into the structural proteins MA, CA and NC, and in some cases additional
proteins. Pol is cleaved into viral enzymes RT and IN (and in some viruses, PR).
Env is cleaved into the surface glycoprotein (SU) and transmembrane protein (TM),
which decorate the viral envelope (Env is cleaved by a cellular protease in the Golgi
rather than the viral PR). Some retroviruses, known as complex retroviruses,
additionally encode accessory proteins, which generally have roles in regulating viral
gene expression, combating host defenses, or increasing infectivity [6]. All retroviral
genomes contain regulatory regions at their 5’ and 3’ ends made up of U5 and U3
respectively, each flanked by a direct repeat, R. Following reverse transcription, these
untranslated elements become rearranged and duplicated, so the cDNA and provirus
contain a directly repeated sequence at each end, a long terminal repeat (LTR), in the

3

configuration U3-R-U5 [21]. The arrangement of the reverse-transcribed genome of
HIV is shown in Figure 1-2A. The LTRs contain sequence elements required for IN
function [22-24] and viral gene expression. U3 contains promoter and enhancer
elements, including host transcription factor binding sites [25]. Sequences in R or U3
in the 3’ LTR form the polyadenylation signal [26].
Virion proteins are translated as Gag, Gag-Pol, Env and Pro (Pro is expressed
as part of Gag or Pol, or individually depending on the virus). Gag, Gag-Pol and Pro
associate with the nascent viral genome to assemble the virion core. Env is targeted
to the cell membrane, from where new virions bud. Budding envelops the core in
cellular lipid membrane studded with the Env protein. Following budding, the virion
polyproteins are processed by the viral protease, leading to structural changes to the
core known as maturation.
The family Retroviridae is divided into two sub-families, the
orthoretrovirinae and the spumaretrovirinae. The orthoretrovirinae have been better
studied, since several members of the family cause disease in animal hosts. The
orthoretrovirinae are classified into six genera on the basis of sequence similarity.
The genera and example members of each genus are listed in Table 1-1. The
lentiviruses, which will be the topic of this dissertation, are a family of complex
retroviruses named for their ‘slowness’. They infect a range of mammalian hosts, and
infection is characterized by long incubation periods, persistent viral replication and
the destruction of hematologic or immunologic cells [6]. This genus contains HIV,
SIV and FIV, which cause immunodeficiency in human, simian and feline hosts
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Genus

Type species

Other examples

Alpharetrovirus

Avian leukosis virus
(ALV)

Rous sarcoma virus (RSV)

Betaretrovirus

Mouse mammary
tumor virus (MMTV)

Jaagsiekte sheep retrovirus (JSRV)

Gammaretrovirus

Murine leukemia virus
(MLV)

Feline leukemia virus (FeLV),
Xenotropic murine leukemia virusrelated virus (XMRV)

Deltaretrovirus

Bovine leukemia virus
(BLV)

Human T-lymphotropic virus (HTLV)

Epsilonretrovirus

Walleye dermal
sarcoma virus (WDSV)

Lentivirus

Human
immunodeficiency
virus (HIV)

Notes
Simple genome; associated with
anemia, sarcoma and other tumors
in avian hosts
Simple genome; associated with
cancer in mammalian hosts
Simple genome; associated with
cancer in mammalian hosts
Complex genome; associated with
leukemia and lymphoma in
mammalian hosts
Complex genome; Infect fish

Simian immunodeficiency virus (SIV), Complex genome; slow, chronic
Feline immunodeficiency virus (FIV),
viral replication in mammalian
Equine infectious anemia virus (EIAV) hosts; can infect non-dividing cells

Table 1-1. Retroviral genera and example members. Adapted from Coffin et al.
[6].
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respectively, and EIAV, which causes anemia in horses. A distinguishing feature of
lentiviruses is their ability to infect non-dividing cells, engendering great interest in
steps of their lifecycle leading up to their interaction with the host genome [27], and
enabling their use as gene delivery vectors in terminally differentiated cell types
(discussed in section 1.9 of this chapter).
1.2 Clinical relevance of lentiviruses
The retrovirus of greatest clinical importance is arguably the complex
lentivirus, human immunodeficiency virus (HIV), identified in 1983 as the causative
agent of acquired immunodeficiency disorder syndrome (AIDS) [28, 29]. HIV is
transmitted by direct sexual contact, contact with blood or blood products, and from
mothers to infants intrapartum, peripartum or through breast-feeding [6]. Both cellfree and cell-associated virus can play a role in transmission [30]. HIV infects
immune cells expressing the receptor CD4, namely T-cells and macrophages.
Primary infection is associated with an acute phase of mononucleosis-like illness,
high viremia and low CD4+ T-cell count 3-6 weeks after transmission [6].
Following acute infection, viral load drops and CD4+ count recovers, but over a
period of several years, untreated infection results in a slow increase in viral load and
decline in CD4+ T-cells. This period of slow decline is known as clinical latency,
and is asymptomatic. Eventually, CD4+ T-cell numbers decline below a critical
threshold, leading to AIDS: increased susceptibility to opportunistic infections, which
ultimately lead to the patient’s death. According to the World Health Organization,
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an estimated 33.4 million people are currently infected with HIV worldwide and 2
million HIV-related deaths occurred in 2008 [31].
While an effective HIV vaccine remains elusive, pharmacological inhibitors
of several steps of the HIV lifecycle have been developed and are used for the
treatment of HIV. Roughly 30 inhibitors have been developed and approved for use
in patients, targeting the entry, reverse transcription, integration or maturation steps of
the viral lifecyle. These are typically administered as highly active antireroviral
therapy (HAART), a cocktail of three drugs taken together to reduce the risk of
development of resistance to any one drug. While the drugs currently in use have
made a remarkable impact on HIV mortality and morbidity, they must be taken
indefinitely and patients frequently develop resistance to them [32, 33], necessitating
periodic changes to the patient’s drug regimen. There therefore remains much interest
in shedding light on the lifecycle of HIV and related lentiviruses, particularly
interactions of the virus with host cell factors, to identify potential novel therapeutic
targets.
1.3 Integration
This dissertation focuses on the integration step of the viral lifecycle. The
ability of retroviruses to integrate into the host genome is responsible for several of
the most challenging aspects of HIV treatment and eradication. Integration of the
genome allows the establishment of latency, prevents complete elimination of viruses
with antiretrovirals [34], and enables archiving of drug resistance mutations [35].
The covalent insertion of viral sequence into the host genome has also contributed to
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genome evolution: roughly 8% of the human genome, for example, is composed of
retroviral sequences and it is thought that some of these elements have been co-opted
for the benefit of the host cell [36]. Finally, as described in detail in section 1.7 of
this chapter, the ability of retroviruses to integrate DNA between their LTRs into host
DNA has enabled their use in gene therapy, but the possibility of this event disrupting
host gene expression is also the cause of safety concerns.
The integration reaction is illustrated in Figure 1-3. It is composed of three
main steps: processing of viral DNA ends, joining of viral to host DNA, and repair of
gaps. The viral enzyme integrase (IN) has been shown to be sufficient for the first
two steps in vitro [19, 20, 37, 38]. IN removes two nucleotides from the 3’ termini of
the viral DNA, leaving recessed 3’ hydroxyl groups [39, 40]. IN then catalyzes attack
by these hydroxyl groups on phosphodiester bonds in the target DNA backbone [19,
20, 41]. This leaves single-stranded gaps between the points of joining on the two
strands, which are probably repaired by host DNA repair enzymes [42].
The integrase protein is proteolytically cleaved from the Gag-Pol precursor
upon virion maturation. IN is composed of three domains: the N-terminal zincbinding domain (amino acids 1-50), the catalytic core (amino acids 50-212), and the
C-terminal DNA-binding domain (amino acids 212-288) [43]. Three conserved
amino acids (D,DX35E, referred to as the catalytic triad) in the catalytic core domain
(CCD) are required for catalysis [44-46]. The structure of the CCD is an RNase Hlike fold, conserved among members of the RNase H phosphotransferase enzyme
family [45, 47, 48]. The catalytic triad is brought together in space, and coordinates
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Figure 1-3. The integration reaction. A. Reverse-transcribed viral DNA (bold lines)
is associated with integrase (IN), probably as a tetramer (green circles), in the preintegration complex. B. Terminal cleavage. IN removes 2bp from the 3’ ends of the
viral DNA, exposing hydroxyl groups and leaving 5’ overhangs. C. Strand transfer.
IN catalyzes nucleophilic attack by the two 3’ OH groups on the phosphate backbone
at two positions in the host DNA (fine lines). The interval between the two positions
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unpaired gaps at each viral-host DNA junction. E. Gap repair. Host enzymes are
thought to fill in the gaps. F. The integrated provirus is identical in sequence to the
reverse transcribed genome, and is flanked by a repeat in the host genome resulting
from gap repair (in the case of HIV, 5bp). Adapted from Ciuffi and Bushman [189].
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two divalent metal cations [49-53]. The core is also thought to function in DNA
binding [24, 54] and contribute to target DNA sequence preference in vitro [55, 56].
The N- and C-terminal domains are thought to promote DNA binding and
multimerization [57-63]. No crystal structure of full-length IN has been published
yet, but two-domain structures show CCDs associated as dimers [64-67], leading to a
model of IN function in vivo as a dimer of dimers [68].
In vivo, integration is carried out by the PIC, a nucleoprotein complex derived
from the viral core [10, 13, 69]. PICs can be isolated from infected cells and carry
out coordinate integration of both ends of endogenous cDNA into target DNA
supplied in vitro [10, 70, 71]. HIV PICs have been shown to contain, as well as IN,
the viral proteins MA, RT, NC and Vpr [15] but very little CA [14]. A number of
host proteins have also been found to associate with purified IN or with the PIC, and
the contribution of such host factors to integration is discussed below and is a focus
of this dissertation.
1.4 Host factors in integration
Attempts to identify candidate integration cofactors have used a number of
approaches. One approach has been to search for host proteins that stimulate
integration by pre-integration complexes. It was observed that gel-filtration of PICs
in the presence of high salt resulted in a loss of integrase activity, which could be
restored by adding back cell extracts. By fractionating such extracts a number of host
factors have been identified, including the non-histone chromatin protein HMGA1 in
HIV PICs [72] and the chromatin-associated protein BAF in HIV [73] and MLV PICs
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[74]. However, further studies of HMGA1 suggested it is not strictly required in HIV
infection [75] and the role of BAF in infection remains unclear [76, 77]. Another
approach has been identifying IN binding partners by yeast-two-hybrid. The
SWI/SNF chromatin remodeling protein Ini1, was identified as interacting with HIV
IN [78], though its role in infection now appears to be in assembly [79]. More
recently, TNPO3/transportin-SR2 was identified by yeast-two-hybrid as interacting
with HIV IN [80], and appears to be an essential nuclear import factor, though it may
also function through CA binding [81]. Similarly, the transcriptional coactivator
LEDGF/p75 was identified by its co-immunoprecipitation with IN overexpressed in
human cells [82]. LEDGF/p75 appears to be an essential lentiviral integration tether
and is discussed in detail below and in Chapters 2 and 3 of this dissertation. Most
recently, genome-wide siRNA screens [83-85] have identified hundreds of candidate
host factors necessary for HIV infection. Potential roles of some of these factors in
integration targeting are discussed in Chapter 5 of this dissertation.
1.5 Genomic distribution of integration sites
Early studies of integration in vitro suggested any DNA sequence could serve
as a target for integration by purified IN or PICs. Relatively weak local sequence
preference [86-89], and a preference for distorted nucleosome-associated DNA [86,
90-92] were observed. The advent of genome sequencing enabled genome-wide
studies of integration in cells, which have shown clear biases in the distribution of
retroviral integration sites with respect to various genomic features [93-95]. Indeed
different genera of retroviruses show different integration site preferences. In a
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number of cell types, HIV [93, 96-98] and other lentiviruses [99, 100] favor
transcription units as integration sites, particularly active genes. In contrast,
gammaretroviruses such as MLV and XMRV show a preference for CpG islands and
gene 5’ ends [95, 101], while alpharetroviruses such as ASLV, betaretroviruses such
as MMTV and deltaretroviruses such as HTLV show relatively random integration
patterns, with weak or no favoring of transcription units [94, 96, 102, 103].
The weak sequence preferences demonstrated by retroviral integrases do not
fully account for the genomic distribution of integration sites [104]. Hypotheses that
have been proposed to explain integration site targeting by retroviruses center around
the ideas of chromatin accessibility or tethering. Since much of the DNA in
mammalian cells is tightly wrapped into higher order chromatin structures, and these
structures change with transcriptional status and cell cycle phase, it may be that
integration can only occur in regions that are in an exposed conformation. The bias
of MLV integration toward DNase I hypersensitive sites [105, 106] and of HIV away
from alphoid repeats located in pericentric heterochromatin [89] lend some support to
this idea. However, the distinct patterns of different retroviruses in the same cell
types are suggestive of virus-specific tethers, rather than simple accessibility.
Consistent with the tracking of integration site preferences with retroviral
genus, viral elements have been shown to determine integration site distributions. In
a study of chimeric HIV viruses bearing MLV IN, Gag or both, viruses containing
MLV IN were found to integrate with an MLV-like distribution, with further
influence of Gag when both MLV proteins were present [107]. The idea currently
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favored in the field is therefore that retroviral PICs are targeted to particular regions
of the host chromatin through interactions between viral and host proteins. Tethering
interactions are well documented in yeast retrotransposons, which are closely related
to retroviruses [108, 109], and artificial fusions of HIV integrase to sequence-specific
DNA-binding domains have been shown to direct integration to their recognition sites
[110, 111]. IN, and other viral proteins identified as determining integration site
preference [107] are obvious candidate binding partners for cellular tethering factors,
though any viral component of the PIC described above could potentially play a role.
1.6 LEDGF/p75 in lentiviral integration
LEDGF/p75 is a ubiquitously expressed nuclear protein now widely accepted
as a cofactor for lentiviral integration. Interest in LEDGF/p75 in the HIV field began
when it was found to interact with overexpressed HIV IN in the nucleus [82] and was
identified as an IN binder by yeast-two-hybrid [112]. The protein was identified as
p75, one of two splice variants from the PSIP1/LEDGF gene, reported to be a
transcriptional coactivator that co-purified with the general transcription factor PC4
[113]. The cellular function of LEDGF/p75 remains unclear. In its initial isolation
with PC4, it was shown to have weak transcriptional coactivator activity, though the
p52 splice variant was more active. Around the same time, the protein was also
isolated from lens epithelium cells [114], and given the name Lens Epithelium
Derived Growth Factor. It has been implicated in cellular stress responses [115, 116]
including apoptosis [117] and tumor angiogenesis [118], and it is disrupted in
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chromosomal translocations associated with acute and chronic myeloid leukemias
[119, 120].
Mice lacking LEDGF/p75 expression have been generated, either by gene
trap disruption [121] or knockout [122]. The mice are viable, showing some perinatal
death due to problems feeding, and a range of phenotypic abnormalities in adulthood,
including low fertility and homeotic defects, but normal lens epithelia. Murine
embryonic fibroblasts (MEFs) derived from these mice, as well as human cell lines
stably knocked down for LEDGF/p75, grow normally and were used in the
experiments described in later chapters.
Figure 1-4 illustrates the domain structure of LEDGF/p75. At its N-terminus
(amino acids 1-325) is a PWWP domain, a nuclear-localization signal, two AT-hook
motifs and three charged regions, which have all been implicated in chromatin
binding [123-125]. The PWWP domain (named for its Pro-Trp-Trp-Pro motif) is
found in a number of chromatin-binding proteins, and is thought to be a member of
the Tudor domain Royal family [126-128]. LEDGF/p75 shows sequence-nonspecific DNA binding [124], but the relative contributions of binding to DNA and
protein in chromatin remain unclear.
p75’s C-terminus contains a domain that binds lentiviral integrases, but not
the IN of other classes of retroviruses [123, 129-131], named the integrase-binding
domain (IBD, amino acids 347-429). On IN, the CCD is minimally sufficient for the
interaction, but is bolstered by contacts with the NTD [112, 132]. Crystal structures
have been solved of the LEDGF/p75 IBD bounds to the HIV IN CCD and NTD, and
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Figure 1-4. LEDGF/p75 domain structure and interactions. PWWP, PWWP
domain; CR, charged region; NLS nuclear localization signal; AT, AT-hooks; IBD,
integrase-binding domain. Arrows represent interaction of various domains with
chromatin (? represents unknown chromatin ligands, the helix represents DNA) or
integrase, represented as a tetramer bound to viral cDNA. Domain structure adapted
from Gijsbers et al. [190].
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show each LEDGF/p75 IBD interacting with two CCD interfaces and one NTD [68,
133]. A number of cellular proteins have been also been shown to interact with
LEDGF/p75’s IBD: JPO2, a c-myc-binding protein [134]; pogZ, a domesticated
transposase with sequence similarity to retroviral IN [135]; and menin, an adaptor
protein associated with the histone-methyltransferase MLL [136].
Consistent with its modular structure – the N-terminus binding chromatin and
the C-terminus binding integrase – LEDGF/p75 has been shown to function as a
molecular tether, recruiting IN (and its other binding partners) to chromatin. When
IN was overexpressed in wild-type cells it colocalized with LEDGF/p75 and
chromatin [82, 129, 132]. Depletion of LEDGF/p75 by RNAi or mutations that
abrogated LEDGF/p75’s interaction with IN or chromatin led to loss of IN nuclear
localization [112, 129, 132, 137, 138]. This led to early proposals that LEDGF/p75
was responsible for nuclear import of IN [132]. However, subsequent studies with
NLS-deleted LEDGF/p75 showed that IN could achieve nuclear localization in
dividing cells due to nuclear-cytosolic mixing during division [123]. Whether
LEDGF/p75 effects transport of IN across the nuclear membrane or acts to retain it on
chromatin after import is not fully determined, though experiments with whole virus
favor the latter model (see below).
LEDGF/p75 enhances IN activity in vitro [82]. This stimulatory activity
requires integrase binding and DNA binding [124, 131]. This may be a biologically
important activity of LEDGF/p75, but caution is warranted in this interpretation
because many nonspecific DNA binding proteins display this activity in vitro.
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LEDGF/p75 also enhances the solubility of IN [130], and protects it from
proteasomal degradation, independently of its chromatin-tethering function [139,
140].
In addition to the above evidence of LEDGF/p75’s role in binding, trafficking
and stimulation of purified or overexpressed IN, its role in cellular infection has also
been demonstrated. It has been suggested to be a component of functional PICs [129]
and partly reconstitute the activity of salt-disrupted PICs [141]. Early studies of
LEDGF/p75 knockdown reported little [142, 143] or no effect [129, 141, 144] on the
level of HIV infectivity. However, a role as an integration cofactor was supported by
the finding that a virus bearing an IN mutation that disrupted LEDGF/p75 binding
while preserving catalytic activity exhibited a severe infection block [112], though
effects on other infection steps were hard to rule out. Similarly, overexpression of the
IBD was reported to act as a dominant negative and inhibit infection at the step of
integration [138], arguing that LEDGF/p75 had a role in HIV integration in vivo.
Based on this model, it seemed probable that LEDGF/p75 could be a
determinant of the genomic distribution of lentiviral integration events. Indeed, a role
for LEDGF/p75 in integration site selection was demonstrated in human cell lines
stably expressing siRNAs against LEDGF/p75 [144]. Knockdown led to a
significant, but partial, reduction in the frequency of integration in transcription units,
specifically in LEDGF-responsive genes (as determined by transcriptional profiling
of knockdown cells) and A/T-rich regions of the genome, hypothesized to be bound
by LEDGF by virtue of its AT-hook motifs.
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The absence of an infectivity defect in knockdown cells generated by a variety
of labs was ultimately argued to be due to residual chromatin-associated LEDGF/p75
expression. Intensified knockdown cells were engineered by stable expression of
lentiviral vectors containing LEDGF/p75 shRNA constructs [140]. In these cells, no
residuum was detected and HIV infection was reduced 31-fold at the integration step
of the viral lifecycle. An increased accumulation of 2-LTR circles was noted, a
species of viral cDNA known to be generated by nuclear NHEJ enzymes and thus
taken as a measure of nuclear import [145, 146]. Rescue of the infection defect
required both chromatin- and integrase-binding capabilities of LEDGF/p75. The
LEDGF/p75 status of the producer cell had no impact on HIV infectivity, arguing that
LEDGF/p75 is not packaged into virions.
At the time this dissertation research was started, integration site selection in
intensified knockdown cells had not been studied. Additionally, a gene-trap
LEDGF/p75 mouse model had been generated, in which lentiviral infection had not
been studied. This left open the possibility that the remaining targeting to
transcription units observed by Ciuffi and colleagues [144] was due to the residual
LEDGF/p75 expression in the cells used, and additionally provided us another model
in which to verify the effect of LEDGF/p75 depletion on lentiviral infection. It
remained unclear:
1. whether LEDGF/p75 was necessary for lentiviral integration site selection in full
2. whether it cooperated with or was antagonized by other determinants
3. whether it was sufficient to determine the sites of lentiviral integration.
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Addressing these questions was therefore one goal of the work described in this
dissertation. In Chapter 2, we seek to determine the necessity of LEDGF/p75 by
studying HIV and EIAV integration sites in intensified human knockdown cells and
MEFs from a gene-trap-disrupted mouse model with undetectable LEDGF/p75
expression. In Chapter 3, we address the issue of sufficiency by using fusion proteins
containing the LEDGF/p75 IBD and alternative chromatin binding domains to
retarget lentiviral integration. In Chapters 5 and 6, we consider other factors that may
contribute to integration site selection.
Another part of this dissertation concerns integration in gene therapy, and we
now turn to that topic.
1.7 Use of retroviral vectors for gene therapy
The ability of retroviruses to covalently integrate their genetic material into
the host genome has made them attractive vehicles for the delivery of corrective
genes in patients suffering from genetic diseases. Generation of a retroviral gene
delivery vector essentially involves replacing the viral genes gag, pol and env with
the host transgene. This is illustrated in Figure 1-2B. The resulting transfer vector,
bearing the transgene, viral packaging signal and LTR sequences, functions like a
retroviral genome. The packaging proteins (Gag, Gag-Pol and Env) must be provided
in trans, since they are absent from the ‘genome’ that bears the transgene. Cells
therefore express, transiently or stably, the transfer vector, a Gag-Pol vector and an
envelope vector, and produce packaged virions [147, 148]. These virions are used to
transduce patient cells, the transfer vector undergoes reverse transcription and
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integration, and the corrective gene is stably expressed. Retroviruses have a coding
capacity of around 7-7.5kb, can be manufactured at relatively high titers, and have a
fairly high transduction efficiency, making them practical transfer vectors [149-151].
Gammaretroviral vectors (based on MLV) were the first to be developed, and
remain the most widely used, with 333 clinical trials completed or in progress
worldwide as of December 2009 [152]. A major limitation of gammaretroviral
vectors is their inability to infect non-dividing cells. In an effort to expand the range
of disorders to which gene therapy could be applied, lentiviral vectors, which are able
to infect non-dividing cells, have recently increased in popularity, with 24 trials
currently completed or on-going.
The greatest success has been in the development of techniques for treatment
of hematological disorders such as SCID-X1, ADA-SCID and CGD, ALD and βthalassemia. In these protocols, bone marrow is harvested from the patient and
transduced ex vixo. Transduced cells are then transplanted back into the patient
following myeloablation, and gene-corrected stem cells reconstitute the bone marrow
[151].
The work of many labs has enhanced the design of transfer vectors to improve
transgene expression and prevent silencing. Some of these elements are illustrated in
Figure 1-2B. Transduction efficiency is improved by the incorporation of sequence
elements to enhance RT and possibly PIC nuclear import, for example a polypurine
tract in the cDNA, the cPPT [153]. Replacement of the viral LTR promoter with an
alternative cellular promoter can enhance transcription initiation, target certain cell
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types and enhance long-term expression [147]. Transcript nuclear export can be
maximized by incorporating an intron or a post-transcriptional regulatory element
such as the WPRE from Woodchuck Hepatitis virus [154, 155]. The risk of transgene
silencing by DNA methylation is reduced by incorporating insulator elements that
prevent the spread of epigenetic modifications from surrounding DNA [147, 148]. A
range of envelope glycoproteins are now also in use, enabling some degree of tissuespecific targeting [156].
One safety concern over the use of retroviral vectors has been the potential for
reconstitution of an infectious retrovirus by recombination of transfer and packaging
vectors. This has been dealt with by separating gag-pol and env sequences onto two
separate packaging plasmids that do not contain overlapping viral sequence elements,
reducing the probability of recombination during vector production [157]. Another
safety issue is the possibility of insertional activation. This is discussed in detail
below, and remains a serious concern, despite various modifications to vector design
intended to mitigate it.
1.8 Insertional activation
Since their discovery, retroviruses have been implicated in carcinogenesis
[158, 159]. Indeed studies of tumor-associated retroviruses have contributed to our
understanding of the development of cancer [6]. Retroviruses can exert oncogenic
effects by encoding an oncogene, either a captured cellular gene [159-161] or a
modified viral factor with oncogenic properties [162]. Alternatively, retroviruses
lacking an encoded oncogene can alter the expression of a host growth control gene
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close to the site of proviral integration by insertional activation.
Insertional activation can be caused by a number of mechanisms [6]. One is
upregulation of transcription of an oncogene by retroviral promoter or enhancer
sequences inserted a short distance upstream of the gene. Alternatively, proviruses
may integrate within a gene, resulting in transcriptional readthrough, forming a
hybrid transcript of viral and host sequence. This hybrid may act as an aberrantly
active growth factor, for example encode a constitutively active oncogene missing a
regulatory domain. Finally, an integrated provirus may separate a growth-control
gene from non-coding regions that modulate its expression. Tumors arising by
insertional activation usually have a long latency – assuming the altered locus has a
dominant phenotype, the initial integration event may impart a growth advantage on
the cell, but additional mutations (second and third ‘hits’) will likely be required for a
tumor to develop. Rarely, retroviruses can promote transformation by inactivating a
tumor suppressor gene, though in this case the other allele must be inactivated as
well.
In a number of clinical trials of retroviral vectors, insertional activation has
resulted in adverse events. In the SCID-X1 trial, for example, 5 of 19 children treated
with a gammaretroviral vector containing the common cytokine receptor γc chain
went on to develop leukemia [163-165]. Analysis of the genomic sites of vector
integration can provide evidence of insertional activation and shed light on the
mechanism of oncogenesis. Integration events that alter the expression of cellular
growth control genes would be expected to impart a growth advantage to the cells
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harboring them. Those cells would therefore accumulate in the treated individual,
and be more frequently recovered upon random sampling of circulating cells and
bone marrow. Such analysis has been carried out for a number of gene therapy trials.
In the SCID-X1 trial, for example, samples from patients who developed leukemia
exhibited integration sites within or near the known growth-control genes LMO2,
BMI1 and CCND2 in blast cells [164]. Clonal dominance was also observed in a trial
of a gammaretroviral vector administered for the treatment of chronic granulomatous
disease, which progressed to leukemia. In this case, both patients developed a clonal
expansion of myeloid cells bearing integration sites in MDS1/EVI1, PDRM16 or
SETBP1 and myelodysplasia [166, 167].
The factors determining the incidence and consequences of insertional
activation are not fully understood, but are likely a combination of vector regulatory
elements, the nature of the transgene, the culture and transduction conditions
employed and characteristics of the target cell [168].
The contribution of cell-intrinsic factors to the incidence of insertional
activation is relatively poorly characterized. The self-renewal properties of the target
cell likely affect the consequences of vector integration. For example, Recchia and
colleagues reported [169] that gammaretroviral transduction of terminally
differentiated T-cells, though altering the expression of a large number of cellular
genes, did not result in clonal skewing as long as 9 years post-transplantation.
Similarly, Kustikova et al. reported that clonal dominance developed following
gammaretroviral transduction of hematopoietic stem cell populations, but not more
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lineage-restricted progenitors [170].
Likewise, the nature of the transgene and the nature of the disorder being
treated is thought to affect the potential for insertional activation. For example, in the
SCID-X1 trial, it is likely that the fact the γc chain was required for the survival of the
targeted cells and that corrected cells expanded to fill an empty hematological
compartment meant that transduced cells already had a growth advantage, increasing
the selective forces driving clonal outgrowth [168].
The determinant of insertional activation viewed as the most straightforward
to control is vector design. One proposed approach to reducing the risk of gene
therapy would be to target integration events to specific sites in the genome, chosen
to lie far from growth-control genes to minimize the risk of insertional activation.
This is not yet a practical approach, but some success has been achieved creating
chimeric proteins to retarget integration. Chapter 3 of this dissertation describes
retargeting of lentiviral integration out of transcription units using such a LEDGF/p75
fusion.
In the absence of targeted integration, numerous vector design modifications
have been proposed to reduce the vector’s impact on the expression of nearby genes.
Notably, many of these features were not present in the vectors used in the clinical
trials and resulting adverse events described above [166, 171]. Use of physiologic
cellular promoters such as PGK or EF1α to drive transgene expression, rather than
strong retroviral promoters, has been shown to reduce transactivation [172]. The
inclusion of insulator elements in vectors, in addition to reducing transgene silencing,
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reduces activation of neighboring genes by proviral promoter and enhancer elements
[173, 174]. Deletion of U3, which contains the viral promoter sequence, from the 3’
LTR of the viral genome reduces transactivation of neighboring genes [175, 176].
Studies of insertional activation with such vectors, termed ‘self-inactivating’ (SIN),
have supported the idea that they are less genotoxic [172, 177], though there remain
examples of tumor development with SIN vectors [173, 178]. Insertional activation
by leaky vector transcription can be reduced by the incorporation of exogenous
polyadenylation signals such as that of SV40 in addition to that in the 3’ U5 [179].
Finally, lentiviral vectors have been proposed to be safer than gammaretroviral
vectors, as discussed below.
1.9 Lentiviral vectors
Until 2008, only gammaretroviral vectors had been used in clinical trials of
gene therapy, though lentiviral vectors have long been attractive due to their ability to
transduce non-dividing cells. Additionally, it was expected that lentiviral vectors
might have a better safety profile. Unlike gammaretroviruses, insertional oncogenesis
is not a common feature of infection with lentiviruses, for example HIV. Though it
has been reported [180], none of the data to date is convincing. It has also been
posited that differences in integration site preferences between letiviruses and
gammaretroviruses might impact their safety profiles [148, 181]. Gammaretroviral
vectors show a strong propensity to integrate at promoters and gene 5’ ends [95],
where transcriptional read-through from the viral LTR can lead to upregulation of the
downstream gene [182]. Lentiviruses, on the other hand, favor integration in the
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bodies of transcription units, avoiding regulatory 5’ regions [93, 94, 98]. Indeed,
studies in tumor-prone mouse models [183, 184] and tissue culture systems [185]
have reported less genotoxicity resulting from lentiviral than gammaretroviral
transduction.
Three clinical trials have been conducted using lentiviral vectors in humans,
and have yielded mixed evidence regarding the consequences of integration. The first
trial involved delivery of an HIV env antisense payload to terminally differentiated Tcells infected with HIV [186], and integration events in these patients showed no
evidence of enrichment of sites in proto-oncogenes following transduction [187]. The
second published trial, to treat ALD, involved delivery with a SIN vector containing
the ABCD1 gene into hematopoietic stem cells [188]. Integration sites in these two
patients also showed sustained polyclonality up to 24 months after transplantation,
and clear clinical benefit was achieved. Thirdly, one patient was treated for βthalassemia with a SIN lentiviral vector encoding β-globin (Cavazzana-Calvo et al.,
submitted), and again clinical benefit was achieved, though in this case a clonal
expansion bearing a site within the proto-oncogene HMGA2 was observed.
Given our limited understanding of the factors determining the consequences
of retroviral gene therapy, the results of the human β-thalassemia trial raised
questions about the possibility of SIN lentiviral vector integration near growth-control
genes imparting a selective advantage and leading to preferential outgrowth of the
target cell. In Chapter 4, we present a study of the distribution of integration sites
from the same lentiviral vector as was used in the human β-thalassemia trial, used to
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treat a mouse model. We sought to determine the generality of the finding in the
human trial and contribute to our understanding of the consequences of integration
with this vector for the infected cell.
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CHAPTER 2 – THE ROLE OF PSIP1/LEDGF/p75 IN LENTIVIRAL
INFECTIVITY AND INTEGRATION TARGETING
The contents of this chapter have been published as part of:
Marshall HM*, Ronen K*, Berry C, Llano M, Sutherland H, Saenz D, Bickmore
W, Poeschla E, Bushman FD. (2007) Role of PSIP1/LEDGF/p75 in lentiviral
infectivity and integration targeting. PLoS One. 2(12):e1340.
*equal contribution
2.1 Abstract
To replicate, lentiviruses such as HIV must integrate DNA copies of their
RNA genomes into host cell chromosomes. Lentiviral integration is favored in active
transcription units, which allows efficient viral gene expression after integration, but
the mechanisms directing integration targeting are incompletely understood. A
cellular protein, PSIP1/LEDGF/p75, binds tightly to the lentiviral-encoded integrase
protein (IN), and has been reported to be important for HIV infectivity and integration
targeting. Here we report studies of lentiviral integration targeting in murine cells
with homozygous gene trap mutations in the PSIP1/LEDGF/p75 locus. Infections
with vectors derived from HIV and equine infections anemia virus (EIAV) were
compared. Integration acceptor sites were analyzed by DNA bar coding and
pyrosequencing. In PSIP1/LEDGF/p75-depleted murine embryonic firbroblasts,
reductions were seen in lentiviral infectivity compared to controls. Reductions in
integration in transcription units were seen, paralleling studies of human models and a
different mutant mouse line. Integration did not become random, however –
integration in transcription units was still favored, though to a reduced degree. New
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trends also appeared, including favored integration near CpG islands. In addition, we
carried out a bioinformatic study of 15 HIV integration site data sets in different cell
types, which showed that the frequency of integration in transcription units was
correlated with the cell-type specific levels of PSIP1/LEDGF/p75 expression.
2.2 Introduction
Early steps of retroviral replication involve reverse transcription to generate a
DNA copy of the viral RNA genome, and integration, which results in the covalent
connection of the viral DNA to host cell DNA (for reviews see [1, 2]). The question
of where retroviruses target DNA integration is central to understanding viral host
interactions. For the virus, selection of favorable sites for viral DNA integration
assists efficient expression of the viral genome after integration [3-6]. For the host,
viral DNA integration can either activate or inactivate gene transcription. One
consequence of integration can be insertional activation of oncogenes and
transformation to malignant growth [1, 2, 7, 8]. Here we present data on the role of a
host-cell encoded protein, PSIP1/LEDGF/p75, that guides integration site selection
by lentiviruses, the viral genus including HIV (henceforth we use "LEDGF/p75"
because this name is widely used in the HIV field).
LEDGF/p75 first came to the attention of the retrovirus field when it was
identified in affinity-based screens for its tight binding to HIV IN [9-11].
LEDGF/p75 tethers ectopically-expressed HIV IN to chromatin [9, 10, 12, 13],
through specific binding domains [14-17], and also protects IN from proteasomal
degradation [18]. LEDGF/p75 binding is specific for lentiviral IN proteins (e. g.
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those of HIV, SIV, FIV, and EIAV) [12, 19, 20], which makes it appealing as a
candidate tethering factor since all lentiviruses tested (HIV, SIV, FIV, and EIAV)
show favored integration in active transcription units [5, 21-32]. The crystal structure
of the catalytic domain of HIV IN (residues 50-212) bound to the integrase binding
domain (IBD) was solved, which showed that a pair of LEDGF/p75-IBD molecules
could bind at symmetry-related positions at the interface of the IN catalytic domain
dimer [33, 34].
Early attempts to determine whether LEDGF/p75 was important for efficient
HIV replication used RNAi knockdowns in human cells, which had either no effect or
quantitatively modest effects on infection [12, 13, 35, 36]. This now appears to be
because incomplete knockdowns left biologically significant amounts of protein
present. More recently, human SupT1 cells with intensified RNAi knockdowns
showed infectivity drops of 30-fold by either HIV or another lentivirus, feline
immunodeficiency virus (FIV), and combining this with dominant interfering proteins
derived from the LEDGF/p75-IBD produced 560-fold inhibition of infection [37].
These findings are supported by additional studies in human cell lines [35, 38, 39].
Early knockdowns of LEDGF/p75 were also analyzed for effects on targeting
of HIV integration [40]. Knockdowns in three cell types were studied, and in each
integration frequency within transcription units was reduced. In addition, other
effects were seen, including an increase in the content of G/C bases around sites of
HIV integration in the knockdown cells. These data supported the idea that
LEDGF/p75 acted as a tethering factor, binding to both HIV and chromatin to direct
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HIV integration into active genes. In support of the tethering model, artificial fusion
proteins in which the LEDGF/p75 IBD was fused to the sequence specific DNA
binding domain of phage lambda repressor were shown to direct favored integration
in vitro near repressor binding sites [24]. Also supporting the tethering idea, function
of LEDGF/p75 in promoting HIV replication requires that both ends of the putative
LEDGF/p75 tether be intact [37].
However, key questions still remained on the role of LEDGF/p75. In all the
models studied, HIV continued to favor integration within active transcription units.
This could either be because residual LEDGF/p75 remaining in the knockdown was
sufficient for residual targeting activity, or because additional host cell factors also
contribute independently to targeting HIV integration. In an effort to address this
issue, we studied mouse cells containing homozygous gene trap mutations at the
LEDGF/p75 locus developed by Sutherland and coworkers [42]. Vectors derived
from equine infectious anemia virus (EIAV) were used in many of the experiments,
allowing effects on HIV and EIAV to be compared. Studies of both lentiviruses
provided strong evidence for the role of LEDGF/p75 in promoting efficient infection
and targeting integration in transcription units. Additionally, new integration
preferences emerged in LEDGF/p75-depleted cells, and some targeting to
transcription units persisted. In data not shown, Heather Marshall in the lab
conducted similar experiments with the human SupT1 T-cell line with intensified
RNAi developed by Llano et al. [37], and obtained similar results, confirming that
murine cells are an appropriate model for LEDGF/p75 function.
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While our study was under way, Shun et al. prepared a mouse strain in which
part of the LEDGF/p75 locus was flanked by Cre recombination sites [41], and the
LEDGF/p75 exon was deleted by exposure to Cre recombinase. Mouse embryonic
fibroblasts were then studied for effects on infection with HIV reporter viruses. In
agreement with our studies, these cells showed a 20-fold reduction in infectivity by
HIV, and also a reduction in integration frequency in transcription units that was
stronger than that reported in human cell knockdowns by Ciuffi et al. [40]. The
mouse cells also showed some new targeting features in the LEDGF/p75-depleted
cells, including increased integration near CpG islands.
In addition to these data on manipulated cell models, we also present
additional bioinformatic studies of 15 published HIV integration site data sets in
different cell types, which revealed a strong correlation between cell type specific
LEDGF/p75 expression levels and the proportion of HIV integration sites in
transcription units. These data provide further support for the generality of
LEDGF/p75 as a determinant of integration target site selection for lentiviruses,
including in primary cells where LEDGF/p75 levels were not artificially reduced.
2.3 Materials and Methods
Cell lines
MEFs were extracted from wild-type and knockout embryos at 13.5 dpc [60]
and cultured in DMEM with 10% FBS, 50µg/ml gentamycin, 110µM betamercaptoethanol, 1X non-essential amino acids, 100µM sodium pyruvate. Primary
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MEFs (prMEFs) were immortalized by the 3T3 protocol, by splitting cells every 3
days to a density of 6X104 cells/ml [61].
Viral particle production and infections
VSV-G pseudotyped HIV vector particles were produced by Lipofectamine
transfection of 293T cells with p156RRLsin-PPTCMVGFPWPRE [62], the
packaging construct pCMVdeltaR9 [63], and the vesicular stomatitis virus Gproducing pMD.G construct. EIAV vector particles were likewise produced by
transfection with p6.1G3CeGFPw (M. Patel and J. Olsen, University of North
Carolina, Chapel Hill unpublished), the packaging construct pEV53B [64], and the
vesicular stomatitis virus G-producing plasmid pVSVG into 293T cells. Viral
supernatant was harvested 38 hours after transfection, filtered through 0.22µm filters,
concentrated by filtration through a Centricon, treated with DNase I, and stored
frozen at -80°C. HIV titer was quantified by p24 ELISA.
For HIV infection, cells were plated onto 6-well plates at a density of 3X105
cells per well and each well infected with 1µg p24. For EIAV, cells were plated into
24-well plates at a density of 4X104 cells per well, and each well infected with 100µl
concentrated virus. Infections were performed overnight in the presence of 10µg/ml
DEAE-dextran. 10 independent HIV infections and 5 EIAV infections were
performed per genotype. 48 hours after infection, 90% of cells were harvested for
integration site cloning and the remainder passaged for an additional 2 weeks to dilute
unintegrated products of reverse transcription and used for QPCR analysis of
integration efficiency.
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Infectivity tests
For quantitative PCR analysis, infected cells were passaged for 2 weeks
following infection to dilute unintegrated products of reverse transcription, then
genomic DNA was extracted using the Qiagen DNeasy tissue extraction kit. QPCR
using HIV late-RT primers and probe was carried out as described in [44] using 50ng
genomic DNA as template. For EIAV, primer and probe sequences are described in
Table S1. 25ng of SupT1 genomic DNA was used as template, 50ng of MEF
genomic DNA. QPCR was performed using Applied Biosystems 2X FAST universal
master mix and Applied Biosystems FAST PCR machine.
Integration site amplification
Integration sites were isolated and sequenced by ligation-mediated PCR
essentially as described previously [46]. Genomic DNA was extracted from infected
cells using the Qiagen DNeasy tissue extraction kit. Up to 2µg of DNA from each
infection was digested overnight using MseI. This was followed by digestion to
prevent amplification of internal viral fragments (from the 5’ LTR) and plasmid
backbone with SacI and DpnI in the case of HIV, and XmaI and DpnI in the case of
EIAV. Linkers were then ligated onto digested products (oligonucleotide sequences
listed below) and nested PCR performed from ligation products. Nested PCR primers
contained 4 or 8 nt barcode sequences between the sequencing primer and LTRbinding portions. These enabled pooling of all PCR products into one sequencing
reaction and subsequent separation of sequences by decoding the barcodes.
Amplification products were gel-purified and sent to the Interdisciplinary Center for
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Biotechnology Research at the University of Florida and the Virginia Bioinformatics
Institute Core Laboratory Facility for pyrosequencing. Sequences have been
deposited in the NCBI database, under accession numbers GS773309-GS815944.
Oligos used
Primer name
EIAV Primer PCR1
EIAV nested PCR Forward
HIV Primer PCR1
HIV nested PCR Forward
MseI Linker Primer for nested PCR
MseI Linker Primer for PCR 1
MseI linker positive strand
MseI linker negative strand
EIAV Q-PCR forward
EIAV Q-PCR reverse
EIAV Q-PCR probe
HIV Q-PCR forward
HIV Q-PCR reverse
HIV Q-PCR probe

Primer Sequence (5' ==> 3')
CCTGTCTCTAGTTTGTCTGTTCG
gccttgccagcccgctcagxxxxAGTTTGTCTGTTCGAGATCCTACA*
CTTAAGCCTCAATAAAGCTTGCCTTGAG
gccttgccagcccgctcagxxxxAGACCCTTTTAGTCAGTGTGGAAAATC**
gcctccctcgcgccatcagAGGGCTCCGCTTAAGGGAC***
GTAATACGACTCACTATAGGGC
GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC
[Phosp]-TAGTCCCTTAAGCGGAG-[AmC7-Q]****
CCG CAA TAA CCA CAT TTG TGA CGC
GCA GAA TCT GAG TGC CCA ATT GTC AG
FAM-AGT TCC GCA TTG GTG ACG CGT TAA GT-Black_Hole_Quencher
TGTGTGCCCGTCTGTTGTGT
GAGTCCTGCGTCGAGAGAGC
FAM-CAGTGGCGCCCGAACAGGGA-TAMRA
*primer B - barcode - EIAV 3'LTR PRIMER (nested PCR)
**primer B - barcode - HIV 3'LTR PRIMER (nested PCR)
***primer A-MSEI LINKER PRIMER (for nested PCR)
**** modifications- [Phosp]=5' phosphate, [AmC7-Q]=3' amine

Bioinformatic analysis.
Integration sites were judged to be authentic if the sequences had a best unique
hit when aligned to the murine (mm8 draft) using BLAT, and the alignment began
within 3bp of the viral LTR end and had >98% sequence identity. Detailed statistical
methods are described in [55].
To control for possible biases in isolating integration sites due to restriction
enzyme sequence distribution, three or ten matched random controls were
computationally generated for each experimental integration site that were the same
distance from the closest MseI restriction site as the experimental site.
Integration site counts in various genomic annotations were compared with
matched random controls by the Fisher’s exact test. Additionally, multiple regression
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models for integration intensity were applied, as described in [55].
For analysis of correlations with gene activity in murine integration sites
(Figures 2-3 and 2-4), transcriptional profiling data from wild-type MEFs analyzed on
the MGU74Av2 Affymetrix microarray were used. Genes represented on the
microarray were ranked by expression level and divided into 4 bins based on
expression level. Integration sites found within genes in each bin were counted as a
proportion of sites found within genes in all bins.
For the analysis of relative gene activity in Figure 2-5, data from two types of
Affymetrix chips were used (HU95A and HU133A). Two probe sets querying
LEDGF/p75 but not p52 were available on each chip (For HU95: 39243_s_at
and 37622_r_at; for HU133: 209337_at and 205961_s_at). To account for
differences in the sensitivities arising from the different chip designs and probe sets,
the values for each cell type were first ranked for each probe set and chip
combination, then the ranked values pooled in the final data set.
2.4 Results
Efficiency of lentivirus infection in murine cells disrupted at LEDGF/p75
Human cells stringently depleted for LEDGF/p75 [37] and murine embryonic
fribroblasts (MEFs) from knockout mice [41] show a block in HIV infection. We
wanted to verify this block in lentiviral infection in MEFs containing the gene trap
disruption of LEDGF/p75 reported by Sutherland and colleagues [42]. Because
residual expression is sometimes detected in gene trap alleles, we used quantitative
RT-PCR to determine the fraction of LEDGF/p75 messages disrupted by the gene
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trap insertion. In samples from homozygous mutant (-/-) cells, amplification of
correct LEDGF/p75 message was sporadically detected at high PCR cycle numbers,
suggesting that rare correctly spliced messages were formed. However,
quantification of correct message formation using SyberGreen quantitative PCR
showed expression of LEDGF/p75 to be below the limit of detection in the -/- cells,
corresponding to a reduction of at least 32-fold compared to the wild type (+/+) cells
(data not shown). Sutherland and coworkers reported LEDGF/p75 protein to be
undetectable [42].
We analyzed infection of MEFs isolated from embryos of +/+ and
homozygous mutant -/- mice after infection with HIV and EIAV. Like HIV IN, EIAV
IN is known to bind LEDGF/p75 [20], and EIAV is also known to integrate in active
transcription units [31], so EIAV is a suitable model for analysis of the influence of
LEDGF/p75 on lentivirus infection. Integration was measured by infecting cells,
maintaining the cells in culture for two weeks to allow loss of unintegrated DNA
[44], then quantifying the viral DNA by TaqMan PCR. HIV integration was reduced
~five fold in the LEDGF/p75 -/- MEFs (Figure 2-1), and EIAV integration was
reduced >50 fold. Thus in the presence of a homozygous mutation of LEDGF/p75,
lentiviral integration was strongly reduced but not eliminated.
DNA bar coding and pyrosequencing to analyze integration site placement
We used the pyrosequencing technology commercialized by 454 Life
Sciences [45] to sequence genomic DNA flanking integrated proviruses. Briefly,
genomic DNA was isolated and cleaved with restriction enzymes. DNA linkers were
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Figure 2-1. Efficiency of lentiviral infection in control and LEDGF/p75disrupted cells. Integration of HIV (A) and EIAV (B) was measured by quantitative
PCR. +/+ control; -/- homozygous LEDGF/p75-disrupted.

55

ligated onto the cleaved ends, then host-virus DNA junctions were amplified using
one primer complementary to the linker and one complementary to the viral DNA
end. A second round of PCR was used to improve specificity and to add recognition
sites for the 454 primers necessary for the emulsion PCR step preceding
pyrosequencing [46]. Pooled DNAs were then sequenced.
Use of DNA bar coding allowed multiple integration site populations to be
studied in parallel [47-49]. The viral DNA primer used in the second round of
amplification contained a short recognition sequence (4-8 bases) abutting the 454
primer that was different for each sample tested. These 4-8 bases are the first
determined in pyrosequencing reads. Thus use of bar coding allowed many samples
to be pooled for sequence determination, then the reads could be sorted into
individual experiments by bar code. A total of 1757 unique integration site sequences
from different virus and cell combinations were determined using this method (Table
2-1). We analyzed integration sites in murine embryonic fibroblasts (MEFs) derived
from the LEDGF/p75 homozygous gene trap (-/-) and control (+/+) mice [42] after
infection with HIV and EIAV. Cells that had been immortalized in culture (iMEF)
were compared to primary MEFs (prMEFs). For all the features discussed below the
results were identical for iMEFs and prMEFs (data not shown), so the two data sets
were pooled in what follows.
Consensus sequences at lentiviral integration sites in murine cells disrupted at
LEDGF/p75
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Cell line
iMEF +/+
iMEF -/prMEF +/+
prMEF -/iMEF +/+
iMEF -/-

Description and LEDGF/p75
status
Murine embryonic fibroblasts
from wild-type mice
(immortalized)
Murine embryonic fibroblasts
from gene-trap mice
(immortalized)
Murine embryonic fibroblasts
from wild-type mice (primary)
Murine embryonic fibroblasts
from gene-trap mice (primary)
Murine embryonic fibroblasts
from wild-type mice
(immortalized)
Murine embryonic fibroblasts
from gene-trap mice
(immortalized)

Virus
HIV vector

574

This report

HIV vector

287

This report

HIV vector

531

This report

HIV vector

209

This report

EIAV vector

70

This report

EIAV vector

86

This report

Table 2-1. Integration site data sets used in this study.
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Number of Source of
Integration sequences
Sites
analyzed

As a first step in the analysis, the favored target DNA sequences at the point
of integration were compared in the presence and absence of LEDGF/p75.
Alignment of target DNA sequences at integration sites has revealed weak inverted
repeat consensus sequences [50-55], the symmetry arising because the favored
sequence features at each of the two viral DNA ends are the same. The presence of
this consensus sequence can be a strong predictor of integration targeting specificity,
particularly over short intervals [55]. For HIV, the favored consensus sequence,
TDG↓GTWACCHA (where the arrow represents the site of integration) has been
synthesized and shown to be a favored integration target site for HIV preintegration
complexes in vitro [52]. EIAV has been reported to favor integration in an A/T rich
palindromic consensus sequence [31]
Integration site sequences were aligned to determine the consensus
palindromic sequence at the point of integration, and results were compared for the
+/+ and -/- MEFs for each virus (Figure 2-2). In both cases, integration in the +/+
MEFs showed the weak consensus seen previously for HIV and EIAV. No major
differences were seen in the -/- MEFs, consistent with previous reports of
LEDGF/p75 depletion [40, 41].
HIV integration targeting in murine cells disrupted at LEDGF/p75
Genome-wide studies of HIV integration targeting in murine cells are
presented in this section and analysis of EIAV integration in murine cells is described
in the next section. The data are summarized in Table 2-2 and Figures 2-3 and 2-4.
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Figure 2-2. Integration site consensus sequence for lentiviral infection of murine
control and LEDGF/p75-disrupted cells. A. HIV in +/+ MEFs. B. HIV integration
in -/- MEFs. C. EIAV integration in +/+ MEFs. D. EIAV integration in -/- MEFs.
The diagrams were generated using the WebLOGO program (weblogo.berkeley.edu).
The y-axis indicates bits of information – perfect conservation of a base would score
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HIV integration in transcription units was decreased in the -/- LEDGF/p75
gene trap cells compared with wild-type. In wild-type cells, 54.3% of experimental
integration sites were in RefSeq genes (see Table 2-2), a significant enrichment over
the 28% seen in the matched random controls (see Figure 2-3). In -/- MEFs, 38.7%
of sites were in RefSeq transcription units, a value that is significantly less than in the
+/+ MEFs (p<0.0001 by the Fisher’s exact test). Significant differences were seen
when the analysis was repeated using other gene catalogs as well (Table 2-2).
We also analyzed the proximity of HIV integration sites to CpG islands. In
wild-type cells integration within 2kb of CpG islands was significantly disfavored
compared with random, while in knockout cells integration was 10-fold enriched over
random (P<0.0001 for the comparison between genotypes)
The frequency of integration within 5kb of RefSeq gene 5’ ends showed a
similar pattern (Table 2-2). Integration levels around gene 5’ ends were significantly
higher than random in the +/+ cells (10.9% of sites), but in the knockout a further
increase was observed (15.5% of sites within 5kb of gene 5’ end) achieving P=0.014
for the comparison between cell types (Fisher’s exact test).
Knockdown of LEDGF/p75 has previously been shown to result in an
increase in the G/C content of HIV integration site sequences [40]. We therefore
analyzed the frequency of integration in regions of varying G/C content (Figure 2-3),
revealing that integration was significantly increased in more G/C rich regions in the /- MEFs (P=4e-16).
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Data Set
HIV in +/+
MEF
HIV in -/MEF
EIAV in +/+
MEF
EIAV in -/MEF
Random
Control

Frequency in Genomic Feature (%)
Transcription Units
<2kb CpG Island <5kb Gene 5' End
Known
RefSeq Ensemble
58.6***

54.3***

60.7***

0.7*

10.9***

42.9***

38.7***

46.0***

6.5***

15.5***

62.9***

58.6***

64.3***

1.4

5.7

41.9

38.4

45.3

12.8***

25.6***

29.7

28

32

1.7

6.8

Table 2-2. Integration frequency in the presence and absence of LEDGF/p75
near mapped genomic features in the murine genome. Significant deviation from
matched random controls according to the Fisher’s exact test is denoted by *
(***p<0.0001, **p<0.01, *p<0.05). The ‘random control’ set shown is the matched
random control set for the ‘HIV in +/+ MEF’ integration set (see Materials and
Methods for generation of matched random controls).
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Figure 2-3. HIV integration distributions in control and LEDGF/p75-disrupted
cells. Integration site distributions are shown relative to genomic features. A.
RefSeq genes. B. CpG islands (plus or minus 1 kb). C. G/C content. Integration
sites from unmodified and knockdown cells were pooled and divided into 10 equal
bins of increasing GC content, and sites in each cell type plotted for each bin. D.
Gene density (250kb window). E. Relative gene expression intensity. For each value
in A-B and D, the measured value for the integration site population was divided by
that of the matched random control to emphasize the departure of the experimental
data from random. P values shown are based on regression analysis (A-C) or Chi
Square test for trend (D-E).
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A variety of features analyzed did not show significant differences between
genotypes, including the response to gene density (Figure 2-3D) and the relationship
between gene activity and integration frequency (Figure 2-3E). We return to the
implications of these findings in the Discussion.
EIAV integration targeting in murine cells disrupted at LEDGF/p75
Consistent with previous reports [31], EIAV’s integration distribution was
similar to HIV’s. Likewise, the effect of LEDGF/p75 was similar. Integration in
transcription units was decreased in the -/- LEDGF/p75 gene trap cells compared with
wild-type, from 58.6% of sites (see Table 2-2 and Figure 2-4) to 38.4% (p=0.016 for
the comparison between genotypes by the Fisher’s exact test).
We also analyzed the proximity of EIAV integration sites to CpG islands and
gene 5’ ends. In wild-type cells integration within 2kb of CpG islands was not
significantly different from random, while in knockout cells integration was 13-fold
enriched over random (P=0.0086; Fisher's exact test). Similarly, integration levels
around gene 5’ ends were not significantly different from random in the +/+ cells
(5.7% of sites), whereas in the knockout a significant enrichment was observed
(25.6% of sites) achieving P=0.014 for the comparison between cell types (Fisher’s
exact test).
We analyzed the correlation between integration frequency and G/C content
using a 5kb window around the integration site. A significant difference between
genotypes was found, with sites from -/- cells being found in more G/C-rich regions
(P=0.001, using regression analysis, Figure 2-4).
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Figure 2-3.
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As seen above for HIV, the frequency of integration near a variety of features
was not detectably altered. Figure 2-4D and E show that the relationships between
integration frequency and gene density and expression were not affected by
LEDGF/p75 genotype.
Studies of lentiviral integration in human SupT1 cells with intensified knockdown of
LEDGF/p75
This work was carried out collaboratively with Heather Marshall, also in the
Bushman lab. She carried out studies of HIV and EIAV infection and EIAV
integration site selection in a human model of LEDGF/p75 depletion, intensified
knockdown SupT1 cells (the TC2 and TL2 cell lines in [37]). Results from human
cells were in strong agreement with those from murine cells presented here. HIV and
EIAV infection were approximately 10-fold reduced in knockdown cells compared
with wild-type or scrambled siRNA-expressing cells (data not shown).
The integration site distribution of EIAV was also altered, and the effects
were in agreement with those described above for murine cells. The frequency of
integration in transcription units in knockdown cells was significantly reduced
compared with control cells, but the proportion of sites in transcription units in
knockdown cells remained enriched compared with random (data not shown).
Integration within 2kb of CpG islands was also enriched in the human cells (data not
shown). In agreement with the data described above, integration preference with
respect to gene density and gene expression was not detectably affected by
LEDGF/p75 depletion (data not shown).

65

Correlation between LEDGF/p75 expression and the frequency of HIV integration in
transcription units analyzed over many cell types
In addition to studying cells with artificially reduced levels of LEDGF/p75
expression, we were interested in natural variation in cellular LEDGF/p75 expression
levels. Different primary cell types and cell lines show different steady state levels of
LEDGF/p75 mRNA. Different cell types also show reproducibly different
frequencies of HIV integration in transcription units (see [40] for examples). We thus
asked whether cell types with higher LEDGF/p75 levels showed higher frequencies
of HIV integration in transcription units.
We analyzed data from 15 HIV integration site data sets for which we also
had transcriptional profiling data on gene activity for that cell type. For each
microarray data set, the expression level of LEDGF/p75-specific probe sets was
ranked relative to all other probe sets on the array for that cell type, thus yielding a
value for relative LEDGF/p75 expression. These values were then plotted against the
proportion of HIV integration sites in transcription units for that cell type (Figure 25). This analysis showed that increased relative LEDGF/p75 mRNA abundance
positively correlated with increased HIV integration frequency in transcription units
(R2=0.61; P<0.0001). Figure 2-5 shows data with experimental LEDGF/p75
knockdowns included (triangles), but the correlation was still significant when the
experimental knockdowns were excluded (P<0.0001), indicating that natural variation
in LEDGF/p75 levels was functionally significant.
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Figure 2-5. Correlation between LEDGF/p75 expression and the frequency of
HIV integration in genes. Data is shown for 15 HIV integration site data sets in 10
cell types. The y-axis shows the percentage of integration events within transcription units of the "known gene" set of human genes for each integration site data set.
The x-axis shows relative expression values for LEDGF/p75 derived from Affymetrix array data (see methods for details). The R-squared value for the fit is 0.6148
(P<0.0001). The references for the data sets used are as follows: Macrophage 1 is
the VSV-G set in [25]; Macrophage 2 is the CCR5 set in [25]; SupT1 [21]; IMR90 1
is the dividing set in [66]; IMR90 2 is the growth-arrested set in [66]; CD4 T [67];
PBMC [22]; Jurkat 1 is the Mse set in [46]; Jurkat 2 is the Avr set in [46]; Jurkat 3 is
the initially bright set in [5]; Jurkat 4 is the initially dark set in [5]; Jurkat p75 knockdown [40][46]; 293T [40]; 293T Scram [40]; 293T p75 knockdown [40].
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Some of the data in Figure 2-5 and in previous studies was generated using
transformed cell lines, leaving open the question of whether natural variation in
LEDGF/p75 levels was functionally important in human primary cells. We repeated
the analysis in Figure 2-5 using only data from human primary cells where
LEDGF/p75 levels had not been altered experimentally, and again found a significant
positive correlation between integration frequency in genes and LEDGF/p75 mRNA
levels (P=0.044). These data indicate that natural variation in LEDGF/p75 expression
levels is a significant determinant of integration frequency in transcription units in
human primary cells.
2.5 Discussion
Here we report studies of lentiviral integration in murine cells with a
homozygous gene-trap mutation disrupting the LEDGF/p75 locus [42]. We present
data from HIV and EIAV, extending the collection of lentiviruses shown functionally
to be affected by LEDGF/p75. Infectivity for both HIV and EIAV was reduced 5-50
fold in LEDGF/p75-depleted cells, in good agreement with data on HIV and FIV
published previously [37, 41] – taken together, these studies firmly establishing that
strong LEDGF/p75 knockdowns strongly reduce HIV infectivity. In data not shown,
target site selection in human cells closely paralleled the effects in murine cells, and
also parallel with studies of another murine LEDGF/p75 mutant [37, 41].
Published studies of integration targeting by LEDGF/p75 have relied on
analysis of cells where the LEDGF/p75 levels were artificially reduced – thus there is
interest in obtaining data on the effects of LEDGF/p75 in cells naturally expressing
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different levels of the protein. We took advantage of the observation that different
cell types differ reproducibly in their frequency of integration in transcription units
[40] to investigate this question. A bioinformatic comparison (Figure 2-5) showed
that higher levels of LEDGF/p75 expression correlated with higher frequencies of
integration in transcription units. The trend achieved significance even when the
analysis was restricted to human primary cells only. Thus the study of natural
variation in LEDGF/p75 expression allowed us to extend the idea that LEDGF/p75
directs HIV integration to transcription units in human primary cells without
artificially reduced LEDGF/p75 levels.
A simple model holds that LEDGF/p75 directs favored integration into
transcription units by tethering. According to this model, one domain of LEDGF/p75
binds to HIV preintegration complexes and the other binds chromatin at active
transcription units. Data from artificial tethering studies in vitro with fusions of the
LEDGF/p75 IBD to a sequence-specific binding domain support this model [56].
The tethering model predicts that LEDGF/p75 should accumulate on active
transcription units, but so far this has not been demonstrated experimentally.
Similarly, it is not known how LEDGF/p75 recognizes active transcription units. One
possible model would be that histone post-translational modifications mark active
transcription units and guide LEDGF/p75 binding. Potentially consistent with this
idea is the finding that HIV integration is positively correlated with several types of
histone post-translational modifications [46].
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Curiously, both this study and Shun et al. [41] showed not only a loss of
integration targeting in LEDGF/p75-depleted cells, but new favored genomic regions
as well. From the previous study alone this might have been an idiosyncrasy, but data
presented here shows a similar response in a second murine model, and in human
cells. In all LEDGF/p75-depleted cell types in both studies, integration became more
favored near transcription start sites and associated CpG islands. The basis for this
trend is unknown. It may be that preintegration complexes normally associated with
LEDGF/p75 become free to integrate near these sites once LEDGF/p75 was removed.
Possibly chromatin at start site regions is particularly accessible and so represents a
default target. It is also possible that a more active mechanism is involved. In
support of this idea is the finding that MLV integration is strongly favored at start
sites [28, 57], while several other integrating elements show near random
distributions [22, 55, 58], suggesting that mechanisms exist to guide preferential
integration near start sites.
A variety of genomic features showed positive correlation with lentiviral
integration in both the depleted cells and controls, indicating that cellular systems in
addition to LEDGF/p75 also influence integration. As increasingly deep annotation
of the human genome accumulates, it may be possible to detect additional
associations between lentiviral integration and particular bound proteins, potentially
allowing identification of host cell factors operating in the absence of LEDGF/p75.
Finally, data presented here and in [37, 41] emphasizes that LEDGF/p75 is
important for efficient HIV replication, suggesting that the interaction between IN
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and LEDGF/p75 may be a tractable target for antiviral therapy. The structure of a
complex of the LEDGF/p75 IBD and the IN catalytic domain have been solved by Xray crystallography [33], and the interaction surface was found to overlap with the
binding site seen previously for the integrase inhibitor tetraphenylarsonium [59].
This supports the idea that small molecule inhibitors, if of high enough affinity, may
be able to disrupt binding of LEDGF/p75 to integrase and so abrogate HIV
replication.
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CHAPTER 3 – LEDGF/P75 HYBRIDS RETARGET LENTIVIRAL
INTEGRATION INTO HETEROCHROMATIN
The contents of this chapter have been published as part of:
Gijsbers R, Ronen K, Vets S, Malani N, De Rijck J, McNeely M, Bushman FD
and Debyser Z. (2010) LEDGF hybrids efficiently retarget lentiviral integration
into heterochromatin. Mol Ther advance online publication Jan 5, 2010.
3.1 Abstract
Correction of genetic diseases requires integration of the therapeutic gene
copy into the genome of patient cells. Retroviruses are commonly used as delivery
vehicles because of their precise integration mechanism, but their use has led to
adverse events in which vector integration activated proto-oncogenes and contributed
to leukemogenesis. Here we show that integration by lentiviral vectors can be
targeted away from genes using an artificial tethering factor. During normal lentivirus
infection, the host cell encoded transcriptional co-activator LEDGF/p75 binds
lentiviral integrase, thereby targeting integration to active transcription units and
increasing the efficiency of infection. We replaced the LEDGF/p75 chromatin
interaction binding domain with CBX1. CBX1 binds histone H3 di- or tri-methylated
on K9, which is associated with pericentric heterochromatin and intergenic regions.
The chimeric protein supported efficient transduction of lentiviral vectors and
directed integration outside of genes, near bound CBX1. Despite integration in
regions rich in epigenetic marks associated with gene silencing, lentiviral vector
expression remained efficient. Thus engineered LEDGF/p75 chimeras provide
technology for controlling integration site selection by lentiviral vectors.
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3.2 Introduction
Lens epithelium-derived growth factor/p75 (LEDGF/p75) is a transcriptional
co-activator [1, 2] that colocalizes with chromatin [3] and interacts with the integrase
(IN) of the human immunodeficiency virus type 1 (HIV-1) and other lentivirinae [47]. RNAi-mediated depletion of LEDGF/p75 results in the relocalization of IN to the
cytoplasm and blocks HIV replication at the integration step of the viral lifecycle [811]. In addition, LEDGF/p75 depletion alters the genomic distribution of lentiviral
integration sites [12-14]. Lentiviruses preferentially integrate in active transcription
units and disfavor promoter regions and locations within 1kb of CpG islands [13-17].
For both HIV and EIAV (Equine Infectious Anemia Virus), integration in
LEDGF/p75-depleted cells is reduced in transcription units, but increased in regions
of relatively high GC content and gene 5’ ends. A model has therefore been proposed
in which LEDGF/p75 functions as a molecular tether, bridging between IN and host
chromatin [11-18].
The integrase binding domain (IBD) alone does not mediate chromatin
binding, but overexpression relocates HIV IN to the cytoplasm and blocks HIV
replication [18,19], likely by blocking function of full length LEDGF/p75. The
mechanism of chromatin association by LEDGF/p75 is poorly understood, but an Nterminal PWWP domain [20], a nuclear localization signal, and two AT hooks are
implicated as important from functional studies [11, 21-23] (Figure 3-1).
Meehan and colleagues recently showed that LEDGF proteins bearing H1.1,
H1.5 and LANA in place of LEDGF’s first 199 amino acids are functional HIV-1
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Figure 3-1. Domain structure of LEDGF/p75 and schematic representation
of LEDGF325-530 fusions. LEDGF/p75 contains an integrase-binding domain
(IBD) in the C-terminus and a combination of chromatin interacting modules
located in the N-terminal end, most notably the PWWP-domain, the AT-hook
domain, and three relatively charged regions (CR1-CR3) influence chromatin
binding. In the lower panel the DNA-binding domain fusions with LEDGF325-530
are depicted, H1-LEDGF325-530 and CBX1-LEDGF325-530, respectively. Protein
elements are drawn to scale. Numbers indicate amino acids of each domain. NLS,
nuclear localization signal; H1, histone H1; CBX1, heterochromatin protein 1β
(formerly HP1β).
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cofactors [24]. Here we used the LEDGF-IN interaction to retarget lentiviral
integration to alternative regions of the genome. We engineered artificial chromatin
tethers by fusing the C-terminal IN binding fragment of LEDGF/p75 to alternative
chromatin binding proteins, expressed these in LEDGF/p75-depleted cells, and asked
whether 1) infection was rescued and 2) integration was retargeted to the regions
bound by the chimeric protein. In a previous study, Ciuffi et al. created fusions of
LEDGF/p75 IBD and the λ repressor DNA binding domain and found increased in
vitro strand transfer activity near λ repressor binding sites [25]. However, this
approach has not yet been used to redirect viral integration in cells.
We compared integration targeting for many hybrids between chromatin
binding proteins and LEDGF/p75, with particular focus on domains with binding
specificities that might be useful during human gene therapy. The heterochromatin
protein 1β (CBX1, formerly HP1β) binds to sites enriched in histone H3K9 di- and
tri-methylation at centromeric heterochromatin and transcriptionally silent regions
[29, 38, 39]. This provides a chromosomal target present at high copy number in
gene sparse regions. We found that a fusion in which CBX1 replaced the chromatininteraction domain of LEDGF/p75 rescued the infection block in LEDGF/p75depleted cells. We characterized proviral integration sites using 454 pyrosequencing
and found integration to be retargeted in the presence of the fusion to genomic sites
bound by CBX1. These regions are preferentially outside transcription units and
normally disfavored for lentiviral integration, but transgene expression from the
vector was nevertheless efficient. These findings open possibilities for targeting of
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gene therapy vectors by using the LEDGF/p75-IN interaction, potentially to genepoor regions where their genotoxic potential may be reduced.
3.3 Materials and methods
Retroviral vector production and transduction
Lentiviral vector production was performed as described [34, 50]. Briefly,
vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped HIV-based particles
were produced by PEI transfection using pCHMWS_eGFP-T2A-fLuc as a transfer
plasmid [34]. EIAV-vector particles were produced likewise using p6.1G3CeGFPw
(M. Patel & J. Olsen, University of North Carolina, Chapel Hill, unpublished) and
pEV53B and VSV-G encoding pMD.G.
For lentiviral transduction experiments, cells were typically plated at
20,000 cells/well in a 96-well plate and transduced overnight. 72 hours later, 90% of
cells were reseeded into two plates (FACS analysis and Luc-assay). The remainder
was cultured for Q-PCR or integration site analysis for at least 20 days to eliminate
non-integrated DNA. Stable cell lines were generated by transduction of the
monoclonal LEDGF/p75 KD cells with retroviral vectors and subsequent selection
with blasticidin (3 µg/ml; Invitrogen, Merelbeke, Belgium).
Q-PCR
Integrated proviral copies were quantified by real-time Q-PCR on gDNA as
reported earlier [13].
Integration site amplification

82

Integration sites were amplified by linker-mediated PCR as described
previously [13]. gDNA was digested using MseI and linkers were ligated. Proviralhost junctions were amplified by nested PCR using barcoded primers. This enabled
pooling of PCR products into one sequencing reaction. Products were gel-purified
and sequenced on the 454 GS-FLX instrument at the University of Pennsylvania.
Oligos used are listed below:
Primer

Sequence

EIAV PCR1
EIAV nested PCR2 (454 primer B-barcode-EIAV)
Linker PCR1
Linker PCR2 (454 primer A-linker)
Mse linker+
Mse linker-

CCTGTCTCTAGTTTGTCTGTTCG
gccttgccagcccgctcagxxxxxxxxAGTTTGTCTGTTCGAGATCCTAC
GTAATACGACTCACTATAGGGC
gcctccctcgcgccatcagAGGGCTCCGCTTAAGGGAC
GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC
[Phosp]TAGTCCCTTAAGCGGAG-[AmC7-Q]

Bioinformatic analysis
For integration sites to be called as authentic, sequences needed a best unique
hit when aligned to the human genome (hg18 draft) using BLAT, the alignment
needed to begin within 3bp of the viral LTR end, and the sequence needed to show a
>98% match to the human genome. Statistical methods are detailed in Berry et al
[37]. Integration site counts were compared with matched random controls (MRCs)
by a Fisher’s exact test (where stated), or by multiple regression models for
integration intensity and a c-logit test for significance [37]. Analysis was carried out
using R (http://www.r-project.org). Histone modification data from Barski et al. [40]
and Wang et al. [41] were used. The number of sequence tags from the ChIP-Solexa
data sets in a defined window around each EIAV integration site or MRC, was
calculated. CBX1 binding sites were analyzed using data from Vogel et al. [44]. For
each DamID probe set available, probes were aligned onto the hg18 draft using
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BLAT, and their associated log2 binding ratios used to select the top 5% of sites. For
each integration site or MRC the average number of high-affinity probes within a
defined window around the site was calculated. Pericentric regions were defined as
1Mb upstream or downstream of the unsequenced gap on each chromosome.
3.4 Results
Generation of cell lines and LEDGF/p75 fusions
This study was conducted in collaboration with Rik Gijsbers from the Debyser
lab. Rik transduced HeLaP4-CCR5 cells with an MLV-based expression vector
encoding two miRNA-based shRNAs [26] and a zeocin resistance cassette to
generate a monoclonal cell line expressing 4% of parental LEDGF/p75 mRNA.
Rik also generated constructs where LEDGF/p75’s chromatin binding region
(aa 1-324, Figure 3-1) was replaced by alternative DNA-binding proteins. LEDGF325530

was fused to linker histone 1 (H1; histone 1, H1F0) and heterochromatin protein

1β (CBX1, formerly HP1β). H1F0 binds to nucleosomes without apparent preference
for the underlying DNA sequence [27], continuously shuttling among chromatin
binding sites [27]. CBX1 is associated with pericentric heterochromatin. CBX1 has a
single N-terminal chromodomain which recognizes histone tails via methylated lysine
residues, for example tri-methylated histone H3 at lysine 9 (H3K9me3) [29, 38, 39].
Both constructs, referred to as H1-LEDGF325-530 and CBX1-LEDGF325-530, were
introduced in LEDGF/p75 depleted cell lines using MLV-based viral vectors and
selected with blasticidin. In parallel, control cell lines complemented with MLV-
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based vectors encoding RNAi-resistant LEDGF/p75 (LEDGF BC) or eGFPLEDGF325-530 were generated.
Viability of the selected cell lines was similar to the parental HeLaP4-CCR5
cell line (data not shown). Expression of the fusion proteins in the knockdown cell
line (referred to as KD) was verified by Western blot and immunocytochemistry with
an antibody against the C-terminal portion of LEDGF/p75 (data not shown). No
LEDGF/p75 expression could be detected in KD cells. Back-complementation of KD
cells with full-length siRNA-resistant LEDGF/p75 resulted in the expression pattern
characterstic of LEDGF/p75, which is dense fine nuclear speckling.
Complementation of KD cells with the H1-LEDGF325-530 fusion resulted in a nuclear
distribution and CBX1-LEDGF325-530 which was distributed in multiple irregularly
shaped foci over the nuclear area during interphase, a pattern paralleling that of wildtype CBX1 [32,33]. In addition to nuclear localization, LEDGF/p75 fusion proteins
were found to mediate chromatin tethering of HIV IN. In accordance with previous
data [3,4], transient expression of IN fused to the monomeric red fluorescent protein
(mRFP-INs) in KD cells resulted in a diffuse fluorescent signal throughout the
cytoplasm and complementation with LEDGF/p75 relocated mRFP-INs to the nucleus
and condensed chromatin. Expression of H1-LEDGF325-530 and CBX1-LEDGF325-530
rescued the nuclear localization of mRFP-INs and the binding to condensed chromatin
(data not shown).
LEDGF hybrids rescue lentiviral transduction
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After demonstrating that the fusions were capable of interacting with HIV-1
IN and tethering IN to chromatin, Rik Gijsbers also assayed the efficiency of
integration by lentiviral vectors. In addition to interacting with HIV IN, LEDGF/p75
is known to interact with other lentiviral integrases [4-5]. Integrated HIV- and EIAVbased vector proviral copies were quantified in the different cell lines. For HIV, KD
cells showed a 5.8-fold decrease in integrated copies compared with wild-type cells,
which was rescued completely upon back-complementation with full-length RNAiresistant LEDGF/p75. Expression of fusion proteins partially rescued integration
(60% and 41% of LEDGF BC integration for H1- and CBX1-LEDGF325-530,
respectively). Similarly, for EIAV, the number of integrated copies in KD cells was
decreased 8.8-fold compared to wild-type cells. Complementing the KD cells with
H1-LEDGF325-530 and CBX1-LEDGF325-530 resulted in a partial rescue of vector
integration (3.3-fold and 6.9-fold increase over KD respectively). Thus expression of
the chimeric proteins partially rescued EIAV and HIV integration.
Sequencing of proviral integration sites
We next asked whether the LEDGF325-530 fusions retargeted integration to
genomic sites bound by the fusion partner. Since HeLaP4 cells contain integrated
HIV LTRs that would interfere with the isolation of HIV provirus, we used the EIAV
vector for distribution analysis. EIAV and HIV integrase both interact with the
LEDGF/p75 IBD [6] and show the same integration site preferences in wild-type [35]
or LEDGF/p75-depleted [13] cells. Integration sites were analyzed as described
previously [13], yielding a total of 2769 integration sites (Table 3-1). Random control
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Cell line
Wild-type
Back-complemented
EIAV sites
Knockdown
H1-LEDGF325-530
CBX1-LEDGF325-530
MRC WT
MRC BC
MRC sites
MRC KD
MRC H1
MRC CBX1

Number of % in RefSeq % <2kb CpG
sites
genes
Island
717
862
213
449
528
2151
2586
639
1347
1584

67.2***
70.2***
51.2***
46.1**
32.6*
37.3
36.9
36.5
36.8
37.8

1.3
1.9
5.6**
3.3
1.1
2.8
2.1
1.9
2.2
2.1

Table 3-1. Integration sets generated in this study and their genomic
distributions. Significant deviation from matched random controls (MRC) according
to the Fisher’s exact test is denoted (*** p<0.0001, ** p<0.01, * p<0.05).
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sites were generated computationally, and matched to experimental sites with respect
to the distance to the nearest MseI cleavage site (matched random control, MRC). In
the analyses that follow, the distribution of experimental EIAV sites is normalized to
that of the MRC sites, as a control for recovery bias due to cleavage by restriction
enzymes [36, 37].
Retroviral integrases show weak but detectable target sequence specificity at
the local site of integration. In line with previous reports [13,14], LEDGF/p75
depletion did not affect the consensus sequence flanking the integration site (Figure
3-2). Likewise, expression of LEDGF325-530 fusions did not alter the consensus
sequence, consistent with the idea that IN binding to local target DNA determines the
sequence preference, independently of the tethering mechanism.
CBX1-fusion directs integration to intergenic regions
Lentiviruses favor integration in transcription units and gene-dense regions
[15, 35]. In the absence of LEDGF/p75 this preference is reduced, and a preference
for CpG islands and gene 5’ ends emerges [12-14]. As an initial survey of the proviral
integration site distribution, we examined the frequency of integration in these
features. In KD cells a reduction in the integration frequency in RefSeq transcription
units from 67.2% to 51.2% was observed (Table 3-1 and Figure 3-3A), as previously
reported for LEDGF/p75-depleted cells [13]. While this reduction was statistically
significant (p<0.0001, Fisher’s exact test), integration events in the KD cells were
still significantly favored in transcription units over random (p=4.8 e-6). In
accordance with previous reports, we found that integration sites in the KD cells were
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Figure 3-2. EIAV integration site consensus is not affected by LEDGF/p75
fusions. Following alignment of 20 bp surrounding EIAV integration sites from
each cell type, a consensus sequence was generated using the WebLogo program
(weblogo.berkeley.edu/logo/cgi). Consensus sequence for integration sites from
A. WT cells B. KD cells C. cells complemented with full-length LEDGF/p75 D.
cells stably expressing H1-LEDGF325-530 E. cells stably expressing CBX1LEDGF325-530. The x-axis shows the position relative to the integration site
(between position -1 and 0). The y-axis shows bits of information at each position (perfect conservation at a position would score 2 bits).

89

Ratio EIAV sites to
matched random control sites

A
2.0

*** *** *** *** *

1.5
1.0
0.5
WT
KD
LEDGF BC
H1-LEDGF325-530
CBX1-LEDGF325-530

0.0
In RefSeq Gene

Percentage of sites

B
45
40
35
30
25
20
15
10
5
0

1

2

3
Expression bin

4

Figure 3-3. Expression of the CBX1 fusion retargets EIAV integration away from
expressed genes. A. Frequency of integration within transcription units, as defined by
the RefSeq gene call. Values are normalized to matched random controls. Asterisks
signify significant deviation from matched random controls, determined by the
Fisher’s exact test. *p<0.05, **p<0.01, ***p<0.0001 B. Distribution of integration
sites with respect to gene expression. Transcriptional profiling data from wild-type
HeLa cells analyzed on the HU133 Affymetrix microarray were used to classify the
expression of genes harboring EIAV integration sites. Genes represented on the
microarray were ranked by expression level and divided into 4 bins. For each cell line,
integration sites found within genes were sorted into the 4 bins. The percentages
shown are the proprtions of sites in each bin out of sites falling in all expression bins.
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favored near CpG islands. Both trends were reversed by LEDGF/p75 backcomplementation. In contrast, expression of H1-LEDGF325-530 did not rescue
integration in transcription units. However, upon expression of CBX1-LEDGF325-530,
integration was significantly disfavored in transcription units compared with random
(p=0.026, Fisher’s exact test), consistent with the distribution pattern of CBX1 in
heterochromatic regions, which are generally gene-poor. Analysis of the distribution
of integration sites with respect to gene expression level of the targeted genes also
provided evidence of retargeting due to expression of the CBX1-LEDGF fusion.
Figure 3-3B shows that EIAV integration sites falling in transcription units showed a
slight shift towards genes with lower expression level according to microarray
analysis of HeLa cells (p<0.0001, comparing CBX1-LEDGF325-530 and WT cells by
the Chi Square test for trend).
CBX1-fusion directs integration to heterochromatic regions
CBX1 is known to bind H3 di- or tri-methylated at K9 (H3K9me2 and
H3K9me3, respectively) via its chromodomain [29, 38, 39], so we investigated
integration near sites of these histone modifications [40, 41]. The H3K9me3 density
near sites of EIAV integration is summarized in Figure 3-4A. In WT cells, integration
was disfavored in areas high in H3K9me3 (p=2.9 e-29), consistent with the role of
H3K9me3 in transcriptional repression and establishment of silent heterochromatin,
features generally disfavored by lentiviral integration. In the KD cells the same
negative correlation remained, though its magnitude was reduced (p=0.0012).
Complementation with LEDGF/p75 restored the negative effect of H3K9me3 to wild-
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Figure 3-4. Expression of the CBX1 fusion retargets EIAV integration into
CBX1-rich heterochromatin regions. A. Relationship of integration frequency to
sites of H3K9me3 (10kb window around each site). B. Integration frequency relative
to density of histone methylation and acetylation density (10kb window around sites).
C. Integration frequency in pericentromeric regions (defined as 1 Mb at the edge of
unsequenced centromeric regions). D. Integration frequency in human chromosome
19 near CBX1 binding sites. See Materials and Methods for detailed explanation of
anaylsis.
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Figure 3-4. continued
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type levels. Integration site distribution in H1-LEDGF325-530 cells paralleled that seen
in KD cells. In cells expressing CBX1-LEDGF325-530, however, the correlation was
reversed, with integration sites showing a clear preference for regions denser in
H3K9me3 (p=1.3 e-13).
We carried out the same analysis using genome-wide ChIP-seq data for a
panel of 39 histone modifications [41]. Figure 3-4B shows correlations between
integration sites and the density of these modifications. Each correlation is
represented as a tile on the heat map, with the color denoting the strength and
direction of the correlation. Histone modifications are grouped into clusters, reported
to colocalize and associate with classes of functional genomic elements [41]. In wildtype cells, EIAV sites positively correlated with histone modifications generally
associated with active transcription, such as all acetylations, and some histone
methylations (shown in blue). Integration sites in wild-type cells negatively correlated
(shown in yellow) with H3K9me3 and other markers reported to be associated with
transcriptionally silent regions (e.g. H3K27me3) and heterochromatin (e.g.
H4K20me3 and H3K79me3) [40, 42, 43]. In KD cells, most of the correlations
persisted, though they were less pronounced. Complementation with LEDGF restored
correlations to wild-type levels. In cells expressing CBX1-LEDGF325-530, however,
most of the correlations were reversed, suggesting a dramatic redistribution of
integration sites. In addition to H3K9me3, the modification bound by CBX1, regions
high in H4K20me3 and H3K79me3 became favored for EIAV integration. The latter
two modifications have also been associated with pericentric heterochromatin.
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Since CBX1 is enriched around centromeres, we compared the frequency of
integration sites in pericentric regions. Integration sites in WT, KD or LEDGF BC
cells did not differ from random (Figure 3-4C). In contrast, in cells expressing CBX1LEDGF325-530, these regions contained 2.7-fold as many integration sites as MRC
sites (p=0.0052, Fisher’s exact test), significantly higher than KD cells (p=0.0236,
Fisher’s exact test). Sites from H1-LEDGF325-530 cells also showed a preference for
these regions, but this was not significantly higher than KD cells (p=0.0851, Fisher’s
exact test).
Finally, we used CBX1 binding sites mapped by DamID [44] to calculate the
average number of CBX1 binding sites around integration sites. Figure 3-4D shows
CBX1 occupancy around EIAV integration sites on chromosome 19 did not differ
from random in wild-type cells and KD cells, and was not altered in H1-LEDGF325-530
expressing cells. However, in cells complemented with the CBX1 fusion, 10kb
windows around integration sites contain 7 times as many CBX1 binding sites as
random (p=2.5 e-4). The same pattern held when integration sites across the genome
were compared to CBX1 binding sites mapped genome-wide (p=0.015, not shown).
Thus the CBX1-LEDGF/p75 fusion redirected integration to sites known to bind
CBX1 and a collection of associated features.
Reporter gene expression remains efficient over time
Having shown that the CBX1-LEDGF325-530 fusion retargets lentiviral
integration to sites bound by CBX1, we wondered whether gene expression from the
vector remains efficient, despite integration in regions rich in epigenetic marks
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associated with gene silencing. Heterochromatin is known to spread to surrounding
chromatin – indeed CBX1 and the other HP1 isoforms are thought to enable this
propagation, by binding trimethylated H3K9 and recruiting the methyltransferase
responsible for depositing the modification, Suv39 [29]. This is thought to account
for the phenomenon of position-effect variegation, an effect first described in
Drosophila, where chromosome rearrangements resulting in the positioning of a gene
adjacent to centromeric heterochromatin resulted in its silencing (reviewed in [51]).
We therefore wondered whether targeting lentiviral integrants to regions bound by the
heterochromatin-associated protein CBX1 would have a similar silencing effect.
Cells lines were infected with an HIV vector expressing luciferase and
luciferase activity measured by Rik Gijsbers 48h post-infection. Luciferase activity
was 7-fold lower in KD cells than WT (data not shown) and was rescued by backcomplementation with RNAi-resistant LEDGF. Fusion of LEDGF325-530 to either the
linker histone H1 or CBX1 partially rescued viral vector transduction (36.3% and
47.5%, respectively, data not shown). Similarly for EIAV, back-complementation of
KD cells rescued vector transgene expression to wild-type levels and fusion of
LEDGF325-530 to linker histone H1 or CBX1 partially rescued viral expression (53%
and 45.1%, respectively, data not shown). Thus, partial reporter gene expression was
observed, mirroring the partial integration rescue observed by provirus QPCR.
We wondered whether the integrants in cells expressing CBX1-LEDGF325-530
might be silenced over time due to the spread of inhibitory chromatin. Reporter
activity was therefore measured over time for the CBX1-LEDGF325-530 cells and
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compared to WT cells, KD cells or KD cells complemented with full-length
LEDGF/p75. Engineered cell lines were infected with an HIV-based vector
expressing eGFP and fLuc [34], and reporter expression was measured in cells over
two weeks. Mean fluorescence intensity (MFI) gradually decreased in all cell lines
over time (Figure 3-5). The relative difference in overall MFI (fold difference to the
first measurement at 72 hrs) reached 4-fold in WT cells or LEDGF BC cells, and
about 2.5-fold in the KD cells. Surprisingly, eGFP reporter activity only decreased
1.5-fold in the CBX1-LEDGF325-530 cells, demonstrating that despite retargeting to
CBX1 binding regions transgene expression remained efficient. Thus, there was no
evidence for the idea that integration in more heterochromatic regions directed by the
CBX1 domain obstructed gene expression from these HIV-based vectors.
In these studies of lentiviral vectors, reporter gene expression is driven by the
CMV immediate early promoter. We wondered if a similar effect would be observed
with LTR promoter elements. Cells were therefore infected with replicationcompetent HIV (NL4.3 strain) and p24 production quantified over time by ELISA
(Figure 3-6). Again, CBX1-LEDGF325-530-expressing cells mediated a partial rescue
of Gag gene expression, to 26.2% of that in WT cells. However, in QPCR-based
assays CBX1-LEDGF325-530 expression mediated 60% rescue of integration,
suggesting that in this case vector expression efficiency may be reduced. It therefore
remains possible that retargeting lentiviral integration to heterochromatic regions
does influence vector expression, though the effects appear to be modest and
promoter-specific.
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Figure 3-5. Effect of retargeting by CBX1-LEDGF325-530 on transgene expression
over time. WT, KD and LEDGF BC cells were used as controls. GFP expression
was assayed at the indicated time point following HIV-based vector (LV CMV
eGFP-T2A-fLuc) infection (dpi, days post infection). Overall eGFP fluorescence over
time is calculated as MFI multiplied by % gated cells and displayed as mean ± stdev
(n=6). Experiment conducted by Rik Gijsbers.
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3.5 Discussion
In this study, we present evidence that LEDGF/p75 can be engineered to
target lentiviral integration to new positions in the genome. Alternative chromatin
binding domains (linker histone H1 or the heterochromatin protein 1β, CBX1, were
fused to the C-terminal portion of LEDGF/p75 (aa 325-530, LEDGF325-530). CBX1
was selected to target sites of H3K9 di- and tri-methylation, which are mapped in the
genome and usually disfavored for lentiviral integration, so retargeting would be
readily identifiable. H1 was used as a control, since it has no known preference for
the underlying DNA sequence. Fusing a new chromatin-binding module to
LEDGF325-530 changed the behavior of this protein from an integration-inhibitor into
an efficient cofactor. Upon challenge by lentiviral vectors, LEDGF325-530-fusions
supported efficient lentiviral transduction and integration compared to KD cells.
Similar data were recently reported by Meehan and co-workers [24], albeit using
LEDGF-hybrids that only lack the PWWP- and AT-hook domain (aa 1-199).
In addition, we characterised proviral integration sites using 454
pyrosequencing. Analysis of the EIAV integration distribution demonstrated that the
CBX1 fusion retargeted lentiviral integration away from RefSeq genes (Table 3-1), to
regions high in H3K9me3 (Figure 3-4A) and CBX1 binding (Figure 3-4D). The
observation that integration can be retargeted away from genes and into
heterochromatin using LEDGF hybrids raises hope for the development of safer
lentiviral vectors for gene therapy. Prior to this study, attempts to retarget HIV
integration employed fusions of IN with DNA-binding proteins [45-48]. Some of
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these showed retargeting as purified enzymes, but until now this approach had limited
effect on the distribution of integration sites in cells.
The CBX1 hybrid provides the first example of global redistribution of
lentiviral integration sites in the cellular genome, and the first instance of
manipulation of a host tethering factor to do so. The success of the CBX1 fusion may
be due to the abundance in the genome of its target ligand compared with site-specific
DNA binding domains previously employed, or perhaps its level of occupancy.
Even though integration was targeted towards regions in the genome that are
generally associated with gene silencing, transgene expression remained efficient
over time (Figure 3-5). Similarly, when the effect of retargeting on a replicationcompetent HIV strain, NL4.3, was tested (where gene expression is driven by LTR
promoter elements) Gag-p24 gene expression and infection spread still occurred,
though there was some evidence that its efficiency might be reduced. This suggests
retargeting integration to heterochromatin may have promoter-specific effects. Based
on the paradigm of position effect variegation, one might have expected an effect on
reporter gene expression [51]. The idea that the genomic location of an integrated
HIV provirus affects its expression would also be consistent with previous studies and
proposed models of HIV latency [52]. These results therefore warrant further
investigation. It may be that expression of the CBX1-LEDGF/p75 fusion protein
interferes with the spread of heterochromatin mediated by endogenous CBX1.
Whether new classes of genes are activated as a result is unknown. Alternatively it
may be that lentiviral LTRs contain unidentified insulator elements. To determine the

101

chromatin structure of integrated proviruses, chromatin immunoprecipitation of
regions of the provirus could be performed. Another way to determine if proviral
expression is reduced by retargeting would be to employ the approach of Lewinski et
al. [52], who looked at genomic features correlating with inducible (instead of
constitutive) provirus expression. Cells were infected with GFP Tat-dependent virus,
selected for stably bright cells and dim but inducible cells and integration site
distributions were compared. This could be used to ask if proviruses that express
poorly are also viruses that show more extreme retargeting.
Our findings open possibilities to engineer viral vectors that incorporate
LEDGF/p75 hybrids to target integration into safe landing sites, thereby reducing the
risk of insertional mutagenesis. Hare and colleagues have recently reported [49] a set
of amino-acid substitutions in HIV IN that abolish LEDGF/p75 binding, together with
mutations in the LEDGF/p75 protein that restore binding. Gene delivery vectors
could thus use an altered IN/LEDGF pair to direct integration, even in the presence of
wild-type LEDGF/p75. To date the altered IN does not show wild-type integration
activity, but this may be improved with further engineering.
Our data also address issues in HIV biology. Our findings strengthen the idea
that LEDGF/p75 is the dominant tether for lentiviral integration. The fact that
integration can be retargeted to genomic regions usually disfavored for integration
indicates that integration in these areas in wild-type cells is disfavored due to the lack
of a tether, rather than to an inherent integration barrier such as steric hindrance
resulting from the condensed chromatin structure. Moreover, we show that
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chromatin-binding proteins with multiple specificities can successfully replace the
LEDGF/p75 DNA-binding elements and rescue HIV infection in a LEDGF/p75
knockdown model. Still, the hybrids did not mediate rescue to wild-type levels, which
leaves open the question of whether some portions of the N-terminus of LEDGF/p75
absent from our fusions stimulate integrase activity or reporter gene expression.
Indeed, a recent study suggested that serine residues 271, 273 and 275 may be
important in LEDGF/p75 cofactor function without affecting DNA or integrase
binding [53].
In conclusion, these results establish that LEDGF/p75 is the dominant
targeting factor for lentiviral integration and that its interaction with lentiviral
integrases can be exploited to develop safe and target-specific lentiviral vectors for
gene therapy.
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CHAPTER 4 – INTEGRATION SITE DISTRIBUTION IN MICE
FOLLOWING THERAPEUTIC GENE TRANSFER TO TREAT βTHALASSEMIA
The contents of this chapter are being prepared for submission:
Ronen K, Negre O, Malani N, Denaro M, Gillet-Legrand B, Leboulch P, Down
JD, Bushman FD. Integration site distribution in mice following therapeutic gene
transfer to treat beta-thalassemia.
4.1 Abstract
Treatment of genetic diseases such as β-thalassemia (β-Thal) requires
covalent integration of therapeutic genes into a patient's chromosome to allow stable
inheritance. The Lentiglobin™ lentiviral vector has been applied to gene therapy for
β-Thal with success in one human patient, but a semi-dominant clonal expansion after
integration in the HMGA2 locus in this patient raised the question of whether
lentiviral integration could alter activity of nearby genes and promote abnormal
cellular growth. Here we have used a mouse model for therapeutic gene transfer and
bone marrow transplantation, using the same vector used to treat β-thal patients, and
investigated the integration site distributions present after 9 months of hematopoietic
reconstitution in five busulfan pre-treated β-Thal mice. The recipient mice
demonstrated correction of the disease and were healthy at time of sacrifice. The pretransplantation integration site distribution was typical of lentiviral vectors, showing
favored integration in genes and gene-rich regions. After hematopoeitic cell
repopulation in mice, integration sites located near genes involved in growth control
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were not enriched. No integration sites in or near HMGA2 were detected. Cells
containing integration sites in genes became less common after growth in mice than
before transplantation, and this was accentuated after subsequent culture of explanted
cells in methylcellulose. This is consistent with selective loss of cells containing
integration sites in genes, possibly due to changes in dosage. Similar results have
been seen in some but not all previous studies. Most importantly, these data in mice
indicate that gene correction can be achieved without any indication of vectorenhanced cell proliferation.
4.2 Introduction
Retroviral vectors have been successfully used in human trials of gene transfer
to treat a number of genetic diseases, including X-linked severe combined
immunodeficiency disorder (X-SCID) [1], adenosine deaminase deficiency (ADASCID) [2], chronic granulomatous disease (CGD) [3] and X-linked
adrenoleukodystrophy (ALD) [4]. However, several adverse events have occurred in
which integration of the therapeutic vector resulted in insertional activation of protooncogenes, contributing to the development of leukemia [5-9]. Thus there has been
intense interest in characterizing the integration profile of gene therapy vectors and
improving their safety.
While the majority of completed trials of retroviral gene transfer have used
gammaretroviral vectors, lentiviral vectors are increasingly used. Their appeal stems
from several observations. Lentiviral vectors, unlike gammaretroviral vectors, infect
non-dividing cells [10]. Additionally, no convincing examples of insertional
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activation of oncogenes and consequent transformation have been reported associated
with HIV infection, though HIV proviruses can affect the activity of nearby genes
[11, 12]. Moreover, studies in tumor-prone mouse models have reported less
genotoxicity resulting from lentiviral than gammaretroviral transduction [13, 14].
One possible explanation for the difference in oncogenic potential between lentiviral
and gammaretroviral vectors may be related to differences in their preferred sites of
integration in the genome. Insertional activation in animal models and human
patients is caused by integrated vector promoter or enhancer elements upregulating
downstream cellular genes [5, 6, 8, 15-19]. Gammaretroviral vectors show a strong
propensity to integrate at promoters and gene 5’ ends [20], and clustering near genes
controlling cell growth and proliferation has been reported [21]. Lentiviruses, on the
other hand, favor integration in the bodies of transcription units, avoiding regulatory
5’ regions [22-24], with no bias for growth-associated genes. The lentiviral
integration pattern may thus be less likely to result to insertional activation, though
other variables such as cell type specificity may also play a role [25]. In the context
of vectors, the engineered transcriptional control elements may also explain the
observed differences between gammaretroviral and lentviral vectors [13, 14].
Three clinical trials have been conducted using lentiviral vectors in humans,
and in each the genomic distribution of integration sites was monitored. The first
tested an anti-HIV therapy by delivering an antisense HIV-env gene to mature T-cells
[26]. Integration events in these patients showed no evidence of enrichment of sites in
proto-oncogenes following transduction [27]. The second trial treated two patients
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with ALD by transduction of hematopoietic stem cells [4]. Integration sites in these
two patients also showed sustained polyclonality up to 24 months after
transplantation. Thirdly, one patient was treated for β-thalassemia by hematopoietic
stem cell transduction with a lentiviral vector encoding β-globin with clinical success
(Cavazzana-Calvo et al., submitted). In the β-Thal trial, the integration site
distribution determined at 19 months post-transplantation showed that ~50% of
integration sites were within the proto-oncogene HMGA2. The integration event was
associated with increased transcription of HMGA2 and expression of a transcript
whose 3’ UTR was replaced by vector sequences. This 3’-subsituted transcript lacked
the target of the repressive miRNA, let-7, contributing to elevated HMGA2
expression along with an increase in the rate of transcriptional initiation. HMGA2
has been implicated as important in persistence of stem cells [28] and is disregulated
in some cancers, including by disruption of the normal gene 3' end [29-32]. While
the treated patient remains healthy, this finding has raised questions about the
possibility of lentiviral integration in or near growth-control genes imparting a
selective advantage and leading to preferential outgrowth of the gene-modified cell.
The same SIN lentiviral vector as was used in the β-Thal clinical trial has
been tested in a preclinical mouse model of β-thalassemia, using a closely related
transduction protocol (Negre et al., submitted). This allows further study of the
vector’s possible genotoxicity, and a comparison of the distribution of integration
sites in the mouse and human studies. Nine months post-transplantation the mice
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showed no apparent pathological abnormalities while demonstrating long-term
resolution of the hematological abnormalities associated with β-thalassemia.
Here we present a study of the vector integration sites recovered from bone
marrow transduction and transplantation of five mice. We observed oligoclonality of
integration sites in all animals. Functional classes of genes close to integration events
showed no significant enrichment in genes encoding growth-related functions.
Integration events with the potential to disrupt onocogene regulation by disruption of
miRNA regulation through the mRNA 3' end were not detectably enriched. We also
observed that integration sites from cells following growth either in mice or in
subsequent cell culture showed a reduced frequency in transcription units and genedense regions, suggestive of selection against integration events within genes during
long term passage.
4.3 Material and Methods
Vector transduction and preparation of bone marrow samples
Vector design and transduction is described in (Negre et al., submitted).
Briefly, clinical grade VSV-G pseudotyped lentiviral supernatant was produced by
transient transfection of HEK293T cells with a 5-plasmid system. Bone marrow cells
were isolated from three-month-old female β-thalassemic mice, injected with 5fluoro-uracil (150 mg/kg) 4 days previously. Nucleated cells were isolated and
transduced for 24h, after which they were washed and resuspended in PBS. 400,000
cells were injected via the retro-orbital sinus into each of five 6-month old recipient
male β-thalassemic mice pre-treated with 4 daily doses of 20 mg/kg busulfan.
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500,000 transduced cells from the transplant inoculum were grown in liquid culture
for 11 days, and 30,000 plated in methylcellulose and cultured for 7 days in triplicate.
Following culture, methylcellulose was dissolved, colonies harvested and genomic
DNA extracted. Recipient mice were sacrificed 9.2 months after transplantation and
bone marrow harvested. 3 million cells from each mouse were used for immediate
genomic DNA extraction, and 90,000 cells from each mouse were cultured in
methylcellulose for 7 days before genomic DNA extraction.
Isolation of integration site sequences
Integration site isolation was performed by ligation-mediated PCR essentially
as described previously [22, 24, 33, 34]. Each DNA sample (420-1000ng) was
digested with MseI and NlaIII separately. Linkers were ligated to the digested
samples and samples treated with ApoI to limit amplification of the internal vector
fragment downstream of the 5’ LTR. Samples were then amplified by nested PCR
and sequenced by 454 pyrosequencing at the University of Pennsylvania DNA
sequencing center. In order to sequence all amplicons in one sequencing run, PCR
primers contained 8bp barcodes between the 454 sequencing primer and the region
complementary to the LTR.
Bioinformatic analysis
Integration sites were determined to be authentic if the sequences began
within 3bp of vector LTR ends, had a >98% match to the mouse genome (mm8 draft),
and had a unique best hit when aligned to the mouse genome by BLAT. All
integration sequences will be deposited in GenBank upon acceptance of the paper for
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publication. Integration sites can be viewed on the UCSC browser at the following
URL (http://genome.ucsc.edu/cgibin/hgTracks?db=mm8&hgt.customText=http://microb230.med.upenn.edu/ucsc/Rone
n-BetaThalSites.bed.gz). Three integration sites were found in sequences barcoded as
more than one mouse and deduced to be likely due to crossover between samples
during PCR (though transduced cells were pooled before transplantation, providing
another candidate explanation). The probable origin of each site was assigned based
on sequence abundance and recovery in multiple samples from the same mouse, and
excluded from analysis of the other mouse from which it was recovered. For each
experimental integration site three matched random control sites were
computationally generated. These sites were matched to the experimental sites in
their distance to the nearest MseI or NlaIII site as appropriate.
The RTCGD cancer gene database is available at http://rtcgd.ncifcrf.gov/.
The expanded allOnco cancer genes list is described at
http://microb230.med.upenn.edu/protocols/cancergenes.html.
Enrichment of integration events relative to various genomic features was
compared between datasets by Fisher’s exact (where stated) or by multiple regression
models for integration intensity and a c-logit test for significance, as described in
Berry et al. [35]. Receiver Operating Characteristic (ROC) analysis was used to
represent the relationship between integration and various genomic features by a
single numerical value [35], which was used to generate a colored heat map.
Genomic features analyzed in Figure 4-3 are as follows. ‘In Refseq’ shows the
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preference for integration within genes called by the Refseq gene call. ‘Gene width’
shows the relationship with the length of the gene harboring the integration site.
‘Intergene width’ shows the relationship with the length of the interval between
genes. Short genes and short intergene lengths are associated with gene-rich regions.
‘Gene start distance’ shows the relationship to the distance to the nearest gene 5’ end.
‘Gene boundary distance’ to the nearest gene 5’ or 3’ end. ‘Refseq count’ shows the
relationship to the number of Refseq genes within a given window around each
integration site (windows shown as 1Mb, 100kb etc). ‘Expression’ is gene activity,
measured in MEFs using Affymetrix microarrays. Genes were ranked for relative
expression and the relationship is shown between integration and the expression level
over given windows around ech site. ‘Top 1/2’ and ‘Top 1/16’ means only genes in
the upper half or sixteenth were scored, respectively. ‘CpG count’ is calculated
analogously to ‘Refseq count’, counting the number of CpG islands in the window
specified. ‘CpG desnsity’ takes the number of CpG islands in the given window and
divides by the number of base-pairs for a density measure. ‘GC content’ denotes the
percentage G/C residues in the sequence surrounding each integration site, in the
window shown. Analysis was carried out in R (http://www.r-project.org).
Ingenuity Pathway Analysis software (http://www.ingenuity.com) was used to
form networks based on gene lists assembled from the gene nearest to each
integration site (Figure 4-2).
miRNA predictions were annotated based on three online tools: miRbase
(http://microrna.sanger.ac.uk/sequences/), TargetScan
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(http://www.targetscan.org/mmu_50/) and miRDB
(http://mirdb.org/miRDB/index.html)
4.4 Results
Isolation of integration sites from Lentiglobin-transduced bone marrow before and
after transplantation
Nucleated cells isolated from 5-fluorouracil-treated 3-month-old βthalassemic mice were transduced with the Lentiglobin vector for 24 hours. Cells
were harvested at this time for integration site analysis (pre-transplantation samples).
Before isolating genomic DNA, cells were subjected to liquid culture or
methylcellulose culture. Methylcellulose culture selects for committed hematopoietic
progenitor cells, which have sufficient replicative capacity to form colonies under the
ex vivo culture conditions. Culturing cells in this way therefore allowed us to study
the integration sites of progenitor cells, and compare them to sites from total bone
marrow, which also includes terminally differentiated cells. Colonies derived from
these progenitors were then isolated from the culture and genomic DNA extracted.
500,000 pre-transplantation cells were cultured in liquid media for 11 days; 90,000 in
methylcellulose-based media for 7 days, yielding about 2000 colonies from myeloid
progenitors. Nine months after transplantation, bone marrow was also isolated for
integration site analysis (post-transplantation). Post-transplantation cells were either
cultured in methylcellulose as above, or DNA was extracted immediately. Three
million bone marrow cells were used for immediate DNA extraction, and 90,000 bone
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marrow cells per mouse were cultured in methylcellulose, yielding about 50 colonies
from myeloid progenitors per mouse.
Vector integration sites were amplified from the genomic DNA as previously
described [17]. Since this method relies on restriction digestion, which has been
shown to introduce a significant recovery bias [17], samples were processed with two
different restriction enzymes in parallel, MseI and NlaIII, in an attempt to maximize
site recovery. Vector-host junctions were sequenced by 454/Roche pyrosequencing,
using 8bp barcodes in the primer to distinguish between sets run simultaneously.
Table 4-1 summarizes the number of integration sites identified, pooling
across the two restriction enzymes used on each sample. Across all sets, we obtained
a total of 31128 integrations passing quality control, representing 1162 unique sites
over all sets. The numbers of unique sites detected in each mouse ranged from 2528, providing an initial measure of the numbers of gene-corrected long-term
repopulating cell clones present.
However, the methods used for integration site recovery are unlikely to
capture all integration sites, so we investigated methods for estimating the size of the
full population. Since two different enzymes were used to isolate integration sites
from each sample, overlap between sites recovered by the two enzymes can be used
to estimate the total number of sites using a capture-recapture approach. Using the
Lincoln-Petersen method [36], the number of unique sites estimated to be present in
each mouse are 58, 48, 75, 140 and 48 for mice 31, 32, 33.1, 33.2 and 34 respectively
(see supplementary table S4-1). In another approach, based on a previous study
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Table 4-1. Integration site data sets used in this study.
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Total reads
5254
5430
10684
4209
709
4458
1105
4696
15177
314
1302
1270
759
1622
5267
20444
3353
3239

Data Set

Pre-transplantation (liquid)
Pre-transplantation (methylcellulose)
Pre-transplantation total
Mouse 31 (uncultured)
Mouse 32 (uncultured)
Mouse 33.1 (uncultured)
Mouse 33.2 (uncultured)
Mouse 34 (uncultured)
Post-transplantation (uncultured)
Mouse 31 methyl-cellulose (methylcellulose)
Mouse 32 methyl-cellulose (methylcellulose)
Mouse 33.1 methyl-cellulose (methylcellulose)
Mouse 33.2 methyl-cellulose (methylcellulose)
Mouse 34 methyl-cellulose (methylcellulose)
Post-transplantation (methylcellulose)
Post-transplantation total
Mouse Lenti Tumor
HIV MEF

631
338
963
38
28
34
25
32
158
5
7
19
43
8
81
201
225
2532

Unique
sites
Vector
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiglobin
Lentiviral
SIN HIV-GFP

Description
BM pre-transplantation (liquid culture 11 days)
BM pre-transplantation (methyl-cellulose culture 7 days)
BM pre-transplantation (all sites pooled)
BM 9 months post-transplantation - mouse 31
BM 9 months post-transplantation - mouse 32
BM 9 months post-transplantation - mouse 33.1
BM 9 months post-transplantation - mouse 33.2
BM 9 months post-transplantation - mouse 34
BM 9 months post-transplantation - 5 mice pooled
BM 9 months post-transplantation (methyl-cellulose culture 7 days) - mouse 31
BM 9 months post-transplantation (methyl-cellulose culture 7 days) - mouse 32
BM 9 months post-transplantation (methyl-cellulose culture 7 days) - mouse 33.1
BM 9 months post-transplantation (methyl-cellulose culture 7 days) - mouse 33.2
BM 9 months post-transplantation (methyl-cellulose culture 7 days) - mouse 34
BM 9 months post-transplantation (methyl-cellulose culture 7 days) - 5 mice pooled
BM 9 months post-transplantation (all sites pooled)
Various tissues from mice treated with lentiviral vectors that developed tumors
Murine embryonic fibroblasts infected in culture

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
[13]
[13]

Reference

where six restriction enzymes were independently used to isolate integration sites
from patients treated for X-SCID (Wang et al., submitted) we asked what proportion
of all sites was recovered by MseI alone or NlaIII alone. Based on that study,
approximately 25% of all unique sites were isolated using either enzyme alone (data
not shown). According to this estimate, the numbers of unique sites in Table 4-1,
which were isolated using both MseI and NlaIII, likely represent ~50% of the total
sites present in the mice.
The number of sites recovered per mouse was lower after methylcellulose
culture than in samples that were not cultured in methylcellulose. Ninety-thousand
cells from each mouse were placed into methylcellulose culture, forming ~50
colonies from which DNA was extracted, and 3 million cells were taken for
immediate DNA extraction. Evidently plating and growth in methylcellulose selected
out a subset of progenitor cells.
Figure 4-1 shows the proportion of the most abundant integration sites
identified in the bone marrow of each transplanted mouse, comparing sites from cells
with and without methylcellulose culture. Each site is classified by the gene it is
either within or closest to, and the abundance of each site is displayed. It can be seen
that integration events post-transplantation were oligoclonal, with levels of clonal
dominance varying from 40% to 70% in different mice.
Integration is not enriched near genes associated with growth or oncogenesis
We next investigated the functional categories of the genes close to integration
sites. Insertional oncogenesis by retroviral vectors most commonly results from
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Arap2
Bcl2
Nfatc3
Prkcb
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Ruvbl2
Sema3d
Nrxn1
Ncam2
St8sia4
Prr16
Csf2rb2
Low freq
Uncultured

Methylcellulose

Atp11b
Ubxn2b
Ash1l
Kcnd2
Trps1
Stt3b
Low freq

Uncultured

Methylcellulose
Trim27
Luzp1
Fat1
Rngtt
Rps29
Oprm1
Prmt6
Manea
Mtdh
Pln
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Basp1
Low freq

Uncultured

Methylcellulose

BC004728
Nipbl
Slc6a20b
Ctage5
Clec14a
Cnot2
Rundc3b
4931440L10Rik
Low freq
Uncultured

Methylcellulose

Tmem164
Ap3d1
Nck2
Slc12a6
E130016E03Rik
Utrn
Frmd4b
Low freq
Uncultured

Methylcellulose

Figure 4-1. Integration site frequencies in individual mice, 9 months after
Lentiglobin-transduced bone marrow transplantation. Each integration site is
labeled by the gene it falls within or the nearest gene, and represented by a different
color. The proportions of sequences recovered of each site are shown. Sites recovered
fewer than ten times were pooled and are displayed as ‘Low Freq’.
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activation of proto-oncogenes or, less commonly, inactivation of tumor-suppressors
following nearby integration. Thus, cells harboring integration sites close to growthcontrol genes can have a selective advantage and become enriched in vivo. We
therefore asked whether integration sites post-transplantation showed evidence of
such enrichment near genes associated with cell growth. Table 4-2 shows the
proportion of unique integration sites that lie within 50kb of a cancer gene, as defined
by studies of insertional activation in mice (the RTCGD [37]). Integration sites from
all 5 mice were pooled in this analysis. The proportion of sites in each data set is
compared to the proportion pre-transplantation. No statistically significant
differences between sets were found by the Fisher’s exact test for proximity to cancer
genes. We also repeated these analyses with an extended list of cancer-related genes
(the allOnco data set from
http://microb230.med.upenn.edu/protocols/cancergenes.html). This list is a
compilation of several gene lists of cancer-associated genes from diverse vertebrates,
in which all genes in any organism were mapped to their murine homologs (see
Materials and Methods). Results with this expanded list also did not show any
statistically significant differences between sets (data not shown).
A related question centered on whether the proportion of sites in each dataset
where the closest gene was an RTCGD gene was increased after growth of cells in
mice. Integration sites were pooled over all mice for this analysis. These values also
did not differ between groups, or from random (Table 4-2).
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Integration Set
Pre-transplantation (liquid)
Pre-transplantation
(methylcellulose)
Pre-transplantation (all)
Post-transplantation
(uncultured)
Post-transplantation
(methylcellulose)
Post-transplantation (all)
HIV MEFs
Mouse lenti tumors
MRC pre-transplantation
(liquid)
MRC pre-transplantation
(methylcellulose)
MRC pre-transplantation
(all)
MRC post-transplantation
(uncultured)
MRC post-transplantation
(methylcellulose)
MRC post-transplantation
(all)
MRC HIV MEF
MRC mouse lenti tumors

Sites in
genes

Sites in
exons

Percent in
exons

Sites in same
orientation as
transcription

Percent same
orientation as
transcription

427

33

7.73

228

53.40

219

13

5.94

112

51.14

641

46

7.18

336

52.42

83

5

6.02

39

46.99

23

0

0.00

13

56.52

89
1745
138

5
106
10

5.62
6.07
7.25

41
860
77

46.07
49.28
55.80

632

34

5.38

301

47.63

370

23

6.22

193

52.16

997

56

5.62

490

49.15

172

4

2.33

78

45.35

75

4

5.33

35

46.67

203

7

3.45

93

45.81

2492
247

127
13

5.10
5.26

1273
133

51.08
53.85

Table 4-2. Integration site frequency in the vicinity of oncogenes.
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The above analysis did not take into account the frequency of recovery of
different integration sites. It could be imagined that an early indication of insertional
activation would be the overrepresentation of integration sites close to genes involved
in growth control. We therefore asked whether there was a correlation between the
frequency of recovery of a particular site and its proximity to genes in the RTCGD.
Integration sites from each set were grouped into 3 bins of increasing recovery
frequency, then the proportion of sites in each bin that fell within 50kb of an RTCGD
calculated. No significant correlations between frequency of recovery and proximity
to cancer genes were found in any data set (data not shown). Thus these data provide
no evidence of clonal expansion of cells bearing integration sites near growth control
genes.
We also used the Ingenuity network analysis software to study the functional
categories of the genes close to integration sites. Clustering of genes into networks
related to growth control after growth in mice would be suggestive of selection for
cells whose growth has been activated by vector integration. Post-transplantation sites
were pooled across mice. The highest-scoring networks based on integration sites
pre-transplantation and post-transplantation are shown in Figure 4-2. It can be seen
that in both cases, genes with functions relating to growth control and cell death are
represented, but growth in mice does not appear to have selected differentiallly for
cells bearing integration sites near such genes.
In the human β-Thal trial (Cavazzana-Calvo et al., submitted) outgrowth was
detected of an integration site in the HMGA2 gene. This was in the sense orientation
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B

Figure 4-2. Network analysis of genes near integration sites before and after transplantation. The highest-scoring
networks generated by the Ingenuity software from the genes closest to integration sites are shown. A. pre-tranplsantation,
network ‘Cancer, Neurological Disease, Hematological Disease’, 30 focus molecules. B. post-transplantation, network ‘Cell
Cycle, Skeletal and Muscular System Development and Function, Cell Death’, 21 focus molecules. Gene names on gray
backgrounds are genes near integration sites; gene names on white backgrounds represent interactors added to the network
computationally to enhance connectivity. The number of genes from the input list used in each network are listed (‘focus
molecules’). Solid lines represent direct interactions, dotted lines indirect.

A

in the third intron of the gene, upstream of miRNA binding sites in the 3’UTR,
leading to 3’ end substitution in the HMGA2 mRNA and potential release from posttranscriptional repression. We thus examined the most abundant sites in each mouse
looking for outgrowth of integration sites lying in the sense orientation in the intron
of a gene with predicted miRNA binding in the 3’ UTR. Of the seven most abundant
sites from five mice under the two culture conditions (Arap2 and Pam in mouse 31,
uncultured and methylcellulose cultured respectively, Atp11b in mouse 32, Trim27 in
mouse 33.1, BC004728 in mouse 33.2, Tmem164 and Ap3d1 in mouse 34), two sites
(Pam and Tmem164) had these properties. Neither of these genes has been associated
with oncogenesis. Three of the seven were in the antisense orientation in introns,
with miRNAs predicted in their 3’ UTR (Atp11b, BC004728, Ap3d1). BC004728
has been associated with metastasis [38, 39], but not tumorigenesis. By comparison,
of 963 unique pre-transplantation sites, 311 were in the sense orientation in an intron
and 284 antisense in an intron. We were thus unable to find any strong evidence
associating clonal expansion with vector integration in the sense orientation within a
growth control gene subject to miRNA regulation.
Integration sites after growth of transduced cells in vivo or in methylcellulose culture
are less frequently distributed in transcription units
Lentiviral vectors show a preference for integration in particular genomic
features, such as the bodies of transcription units and gene-rich regions of the genome
[20, 22, 23, 35]. Figure 4-3 shows a heatmap representing the genomic distribution of
integration sites in four types of samples – pre-transplantation and post-
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All expression 1Mb
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Figure 4-3. Heat map illustrating genomic distribution of integration sites. Favoring or disfavoring of a genomic feature within a window around integration sites in each
data set is represented as a colored tile. The color is determined by ROC curve area
comparing the density of the feature near experimental sites and matched random
control sites. See Materials and Methods for explanation of genomic features. The
p-value for the comparison with pre-transplantation liquid culture, determined by a
logistic regression method that respects the pairing in the data (clogit), is overlaid on the
heatmap tile (*p<0.05; **p<0.01; ***p<0.001).
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transplantation, each with and without methylcellulose culture. For this analysis
integration sites from all mice were pooled within a sample type. For each genomic
feature, favoring or disfavoring of integration in the feature compared to random is
represented by red or blue coloring respectively. The integration site distribution pretransplantation was consistent with previously published studies, with a favoring of
transcription units and regions with high gene density, narrow genes, and high CpG
island density. However, post-transplantation and particularly following
methylcellulose culture these trends weakened and in some cases reversed (asterisks
represent statistically significant deviations from the pre-transplantation liquid culture
dataset).
Figure 4-4 shows a graphical representation of the frequency of integration in
transcription units in each set. It can be seen that while integration pretransplantation is significantly enriched in RefSeq transcription units, cell growth
both in mice and in methylcellulose decreased the preference for provirus
accumulation in transcription units. 67.7% of integration sites pre-transplantation
without culture were found in transcription units. In pre-transplantation cells cultured
in methylcellulose, 64.8% of sites were in transcription units (p=0.0097 for the
difference between the two). Integration in post-transplantation cells in liquid culture
was 52.5% in genes (p=0.014 for the difference with pre-transplantation uncultured
cells) and in post-transplantation cells grown in methylcellulose culture 27.7%
(p=1.59e-6 for the difference with pre-transplantation uncultured cells). Integration
in transcription units is thus below the level expected by chance after growth in mice

129

Ratio Integration Sites to Control Sites

2.0
**

*

***

1.5

1.0

0.5

0.0
In RefSeq Gene
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Figure 4-4. Integration in transcription units. The proportion of integration sites in
each data set within or outside of transcription units are shown, normalized to matched
random control sites (indicated by the horizontal line). Significant differences from
pre-transplantation (liquid culture) sites is denoted by asterisks (*p<0.05; **p<0.01;
***p<0.001).
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and culture in methylcellulose, suggestive of selection against cells with integrated
proviruses disrupting genes sensitive to dosage changes.
We therefore asked whether any bias in the orientation of the provirus relative
to transcription or integration in introns versus exons could be seen, since proviruses
in different orientations may have different effects on host gene activity. No
statistically significant effects were seen (Table 4-3). We thus conclude that provirus
accumulation within transcription units was lower after prolonged growth, but that
this was not associated with a bias in provirus orientation relative to the host
transcription unit.
4.5 Discussion
The safety of lentiviral vectors for gene delivery has been a matter of intense
interest in the gene therapy field, with extensive resources invested in optimizing
vector design to minimize the risk of genotoxicity. Trials of gammaretroviral vectors
in humans have led to adverse clinical events associated with clonal enrichment of
integration sites near oncogenes and tumor-suppressors, but the three human trials of
lentiviral gene therapy have not led to clinical adverse events to date. In the third
trial, involving transduction of hematopoietic stem cells for the treatment of βthalassemia, relative clonal dominance of cells containing a site in the proto-oncogene
HMGA2 was observed (Cavazzana-Calvo et al., submitted), though the patient
remains healthy. Here, we present a study of integration by the lentiviral vector from
this study in a mouse model of β-thalassemia.

131

Integration Set
Pre-transplantation (liquid)
Pre-transplantation
(methylcellulose)
Pre-transplantation (all)
Post-transplantation
(uncultured)
Post-transplantation
(methylcellulose)
Post-transplantation (all)
HIV MEFs
Mouse lenti tumors
MRC pre-transplantation
(liquid)
MRC pre-transplantation
(methylcellulose)
MRC pre-transplantation
(all)
MRC post-transplantation
(uncultured)
MRC post-transplantation
(methylcellulose)
MRC post-transplantation
(all)
MRC HIV MEF
MRC mouse lenti tumors

Sites in
genes

Sites in
exons

Percent in
exons

Sites in same
orientation as
transcription

Percent same
orientation as
transcription

427

33

7.73

228

53.40

219

13

5.94

112

51.14

641

46

7.18

336

52.42

83

5

6.02

39

46.99

23

0

0.00

13

56.52

89
1745
138

5
106
10

5.62
6.07
7.25

41
860
77

46.07
49.28
55.80

632

34

5.38

301

47.63

370

23

6.22

193

52.16

997

56

5.62

490

49.15

172

4

2.33

78

45.35

75

4

5.33

35

46.67

203

7

3.45

93

45.81

2492
247

127
13

5.10
5.26

1273
133

51.08
53.85

Table 4-3. Integration in gene features.
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We found that 9 months after transplantation integration sites in the bone
marrow were oligoclonal. The genes closest to integration sites did not show
evidence of enrichment in growth-related functional categories relative to genes
targeted in pre-transplantation sites. Similarly, no enrichment of integration sites
within 50kb of proto-oncogenes was found post-transplantation, and no relationship
between the proximity of integration sites to oncogenes and site abundance.
We estimated the numbers of gene-corrected progenitor cells in each mouse to
be roughly 50-150 based on the numbers of unique integration sites recovered and
upward corrections to account for sparse sampling. It is of interest to compare these
numbers to those expected based on estimates of stem cell proportions in bone
marrow. A total of 400,000 transduced cells were transplanted into each mouse. It
can be estimated that following treatment with 5-fluorouracil mouse bone marrow
contains 1 in 10,000 stem cells [40-42]. In the transduction conducted in this study,
an average of 70% of cells were transduced (Negre et al, submitted), so recovery of
about 28 clones would be expected on average per mouse. The numbers of clones per
mouse estimated from vector marking were somewhat higher, ranging from ~50-150
clones. We note that biases in recovery due to use of restriction enzyme cleavage
would tend to inflate the estimates by artificially reducing the overlap between sets,
possibly in part accounting for the differences. However, the estimates from vector
marking and stem cell counts were reasonably close, reinforcing the accuracy of
estimates for both stem cell numbers and unique integration sites.
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When initiating the integration site analysis, one question was whether we
would see in mice the dominance of an integration site similar to that found in
HMGA2 in the human trial. In the human trial, integration of the Lentiglobin vector
resulted in 3’ end substitution of the gene as well as an increase in the rate of
transcription initiation. The 3' end substitution removed a miRNA binding site in the
3’ UTR. In mouse, HMGA2 has not been reported to be an oncogene. However,
there are other examples insertional activation by 3’ end substitution in the mouse.
Pim1 and Gfi1 are oncogenes activated in T-cell lymphomas by substitution of their
normal 3’UTRs, which contain miRNA binding sites [15, 43, 44]. Retroviral
integration downstream of the oncogenes Fgf3 (int-2) [45] and c-myc [46] has also
been associated with oncogenic transformation. We thus might have seen enrichment
of integration sites near these genes following transplantation into mice, but this was
not the case. The closest site to Pim1 was 80,427bp upstream of the 5’ end in an
intergenic region, the closest to Fgf3 was over 3Mb upstream and lying within
another gene, the closest to c-myc was over 10Mb upstream in an intergenic region.
Of the seven most abundant sites recovered from the five mice, none were strong
candidates for activation and clonal skewing by 3' end substitution of known growth
control genes. Overall, the results in mice did not detectably recapitulate the clonal
skewing associated with insertion in the HMGA2 third intron seen in the human βthalassemia trial.
The main detectable difference in integration site distribution between pretransplantation and post-transplantation samples was an effect on the frequency of
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provirus accumulation in transcription units. We found that growth of transduced
cells in mice or, to a greater extent, in methylcellulose was associated with a decrease
in the favoring of integration in transcription units. We carried out a meta-analysis of
previously published integration site datasets that have compared the proportion of
lentiviral integration sites in transcription units pre-transplantation and posttransplantation into mice or humans. Shown in Table 4-4 are data from three
published studies where cells were transduced by a lentiviral vector and transplanted
into mice or humans, and vector integration sites were analyzed before and after
transplantation. We found that two of the three studies (one to treat Wiskott-Aldrich
syndrome in mice [47], and one to treat HIV in humans [27]) showed a decrease in
the frequency of integration in transcription units after transplantation, though only
one difference was statistically significant (Table 4-4). Evidence of selection against
other retroviral elements integrated in genes can also be found. Reduced preference
for integration in transcription units has been observed in patients chronically infected
with HTLV, compared with ex vivo infections [48]. Similarly, it has been reported
that evolutionarily older endogenous retroviruses are found less frequently in
transcription units, in both mouse and human [49-53], likely reflecting selection
against cells bearing integrated proviruses in transcription units. A potential
explanation for our results would be that integration of lentiviral vectors into
transcription units disrupted expression of the gene, and that this more often leads to a
fitness cost for that cell than a fitness advantage. The effect could be at the
transcriptional level, involving a change in mRNA levels, or via production of
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Table 4-4. Frequency of integration in transcription units in published studies.
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This study
Lentiviral transduction of Lin- cells to
treat a mouse model of WAS
Lentiviral transduction of human
CD4+ T cells to deliver an antisense
HIV env gene
Lentiviral transduction of bone
marrow and transplantation into
tumor-prone mice

Study

LTR

HIV full
LTR
HIV SIN

[27]

[13]

PGK

WASp

Beta-globin

Promoter

HIV SIN

HIV SIN

Vector

[47]

Reference

80.7

56.0

6-10 months (mice sacrificed
when tumors observed)

70.1

67.7

58.0

78.2

59.2

51.2

N/A

0.033

0.192

0.014

Percentage in gene Percentage in gene
P value
pre-transplantation post-transplantation

6, 14, 28 or 32 weeks

5 or 10 weeks

9 months

Time of growth in vivo

abnormal proteins. Maruggi et al. [12] showed that lentiviral vectors caused
transcriptional deregulation (both up- and down-regulation) of genes within 200kb of
integration events. The frequency of this effect for lentiviral vectors was lower than
for gammaretroviral, and the nature of the internal promoter appeared to be important.
Thus effects on gene dosage may have resulted in some cells having a growth
disadvantage that became evident after long-term proliferation.
In summary, our data show that gene transfer with the Lentiglobin vector used
in the human clinical trial was not associated with clonal skewing during
reconstitution of mice. However, our observations are consistent with a model in
which the integration of a lentiviral vector in or near genes influenced the target cell
via effects on gene activity. Surprisingly, however, it seems that the most common
consequence in this study was a growth disadvantage, since cells with integrations
within genes appear to have been selected against during growth. Following the
findings in the human β-thalassemia trial, the results of this study are reassuring, but
suggest more detailed analysis of the effects of integrating lentiviral vectors on
cellular gene expression and associated fitness costs may be warranted.
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CHAPTER 5 – NOVEL HOST FACTORS IN HIV INTEGRATION SITE
SELECTION

5.1 Abstract
Three genome-wide siRNA screens have recently been published identifying
host factors necessary for HIV infection. There has been much interest in
characterizing in more detail the effects of identified factors and possible mechanisms
of action. We analyzed a number of these host factors, and additional candidate host
factors identified by other means, that appear to act at the integration steps of the
replication cycle. In previous studies, LEDGF/p75 was found to be important for
efficient infection, and to act as a targeting factor directing HIV integration to active
transcription units. We used 454 sequencing of integration sites to ask whether any
of the newly identified factors that are important for efficient integration also
influence integration targeting. We carried out bioinformatic analysis of HIV
integration sites isolated from cells treated with siRNAs against PRPF38A, MAP4
and SETD2. These data suggest integration site selection is altered when under these
conditions, though whether these effects are due to depletion of these factors or a
more indirect mechanism is unclear. Common themes emerge from the analysis of
these knockdowns, with diminished enrichment of integration sites in transcription
units and gene-rich regions compared with integration in control cells. Surprisingly,
the patterns differ from that observed in integration sites from LEDGF/p75-depleted
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cells, suggesting that LEDGF/p75 may not be the only host factor responsible for the
characteristic genomic distribution of HIV integration sites.
5.2 Introduction
Integration is a necessary step of the HIV lifecycle, whereby the reversetranscribed viral genome becomes covalently joined to the genome of the infected
cell. In vitro, the viral protein integrase (IN) is sufficient to mediate the integration of
donor into target DNA [1-3], and the reaction shows weak specificity for target
sequence [4-6]. However, in the cell, IN catalysis takes place in the context of a large
nucleoprotein complex, the pre-integration complex (PIC), into host chromatin in the
nuclear environment. A number of host proteins have been shown to interact with the
PIC [7-11] with potential roles in infection. Furthermore, integration occurs in a nonrandom distribution in the host genome, which is not accounted for by IN’s weak
sequence preference [12-14]. Integration site preferences vary between retroviral
classes, with lentiviruses such as HIV showing a preference for active transcription
units and gammaretroviruses such as MLV showing a preference for CpG islands and
gene 5’ ends [13, 14]. The fact that these preferences track with retroviral genus but
are not seen in in vitro integration by purified IN or PICs suggests that viral
components of the PIC likely interact with host proteins or chromatin structure to
influence the distribution of integration events in the genome.
Indeed, this prediction has been confirmed by studies with the host protein
LEDGF/p75 [15, 16]. LEDGF/p75 was identified as a binding partner of lentiviral IN
[11, 17], and was shown to mediate IN chromatin binding [18, 19], protect IN from
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proteasomal degradation [20] and stimulate IN in vitro activity [11]. Human and
mouse models of stringent LEDGF/p75 depletion have shown that LEDGF/p75 is a
necessary integration factor: in a knockdown or knockout integration by HIV or a
related lentivirus EIAV were blocked 5- to 30-fold [21-23]. Furthermore, integration
in the absence of LEDGF/p75 showed a different distribution around the genome
from that in wild-type cells. In LEDGF/p75-depleted cells, the preference for
integration in transcription units was diminished [22-24]. Additionally, the GC
content of the sequence around integration sites was observed to increase and
integration in CpG islands became favored in the absence of LEDGF/p75. This has
led to a tethering model of integration placement, whereby a chromatin-bound host
factor interacts with a viral component of the PIC and tethers integration events to the
regions around its binding sites. In the case of LEDGF/p75, this model has been
further confirmed through the demonstration of integration retargeting by expression
of fusion proteins containing the IN-binding portion of LEDGF/p75 fused to
alternative DNA binding domains (as described in Chapter 3) [25, 26].
However, studies of LEDGF/p75 in integration targeting leave some open
questions. Firstly, LEDGF/p75’s cellular role, binding partners and mechanism of
chromatin interaction remain partially understood, raising the question of whether
other factors might participate in this tethering mechanism. Secondly, while
depletion of LEDGF/p75 has marked and significant effects on the distribution of
lentiviral integration sites, sites are not randomly distributed in its absence,
suggesting other factors may contribute.
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We sought to investigate alternative integration site determinants. In
considering candidate factors we reasoned that novel tethering factors would likely
phenocopy the known tethering factor, LEDGF/p75. We therefore focused initially
on host proteins whose depletion from the cell, like LEDGF/p75, led to an infection
block at the step of integration, and analysed the distribution of HIV vector
integration sites in cells depleted for these factors. A large number of candidate
factors was provided in the form of hits from a recent genome-wide siRNA screen by
König et al. that identified factors necessary for HIV infection [27]. We report here
integration site data from cells depleted by siRNA knockdown for two factors
identified as hits by König et al. PRPF38A is a splicing factor, annotated in the
human genome by its homology to the yeast protein PRP38, which is required for
spliceosome maturation [28]. It was identified as a factor necessary for integration in
the König et al. screen. MAP4 is a microtubule-associated protein involved in
microtubule assembly and cell cycle progression [29, 30]. It was independently
identified in two genome-wide siRNA screens [27, 31] and has also been reported to
interact with LEDGF/p75 by yeast-two-hybrid (Sumit Chanda, personal
communication). We additionally investigated SETD2/HYPB, a histone methyltransferase that methylated histone 3 on lysine 36 [32, 33], a modification that is
found in the bodies of transcription units and closely follows the distribution of HIV
integration sites in the genome [26]. SETD2 recruits to active genes several other
proteins involved in mRNA processing and export [34]. One of these is IWS1, which
has been shown to bind LEDGF/p75 (Katherine Jones, personal communication).
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Knockdown of SETD2 led to a reduction in HIV infection efficiency, though the gene
had not been identified as a hit in genome-wide siRNA screens. We found that
depletion of PRPF38A, SETD2 and MAP4 resulted in an altered distribution of
integration sites, and common themes emerged from the changes: knockdown of all
genes led to a slight reduction in the frequency of integration in transcription units
and a shift of integration to less gene-dense and GC-rich regions. In data not shown,
from Troy Brady in the lab, knockdown of nuclear import factors TNPO3 and
ANAPC2 showed similar effects. In order to rule out off-target effects, we expressed
an siRNA-resistant form of SETD2, and found that the infection block induced by
siRNA-treatment was not rescued. Thus, the significance of these effects is unclear.
Possible interpretations are discussed.
5.3 Materials and Methods
Cell culture and transfection
293T cells were cultured in Dulbecco’s Modified Eagle Medium with
Glutamax (Invitrogen), 10% FBS (Sigma) and 50µg/ml gentamycin (Sigma). For
siRNA treatment, cells were reverse-transfected. Cells were seeded in 12-well plate
format, 100,000 cells to a well in antibiotic-free DMEM with 10% FBS. siRNAs
were incubated with Optimem serum-free medium (Invitrogen) and RNAiMax
transfection reagent (Invitrogen), as per manufacturer’s instructions, and added to the
cells at the time of seeding. 37.6pmol siRNA and 1.88ul RNAiMax were used per
well. For co-transfection of siRNAs and rescue plasmids, reverse transfection was
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carried out in the same way, using 37.6pmol siRNA, 500ng plasmid DNA and 1.88ul
RNAiMax were used per well.
siRNAs used
siRNAs against SETD2 were from Qiagen (siRNA 1 in the text is HYPB_1,
catalog number SI00103292) and Ambion (siRNA 2 in the text has sequence
GUGAAGGAGUAUGCACGAAtt). siRNAs against PRPF38A and MAP4 were
from Qiagen (catalog numbers SI00395808, SI00395815, SI00627809, SI00627816).
The control luciferase siRNA was from Qiagen (GL2, catalog number 1022070).
siRNA-resistant cDNA cloning
SETD2 cDNA was purchased from Open Biosystems (clone ID 40125715).
Site-directed mutagenesis was performed using the Quikchange kit (Stratagene).
Two sets of 7 synonymous mutations were introduced separately, to each of the
regions targeted by the siRNAs used. The coding sequence was then amplified to
incorporate restriction enzyme sites (primers kr225,
AGTCCAagatctagaGAAAGAAGAGGCAAGTATTCTTC and kr227,
agtccaGTCGACctcgagTCACTCTAATTCAGTGTCCTCTTTGG). The amplicon
was digested with BglII and SalI and inserted into a plasmid containing a 3xFlag tag,
digested with BamHI and SalI. Flag-tagged SETD2 was then cut out using AgeI and
SalI and ligated into a vector based on the MLV-based CMV-promoter-driven
expression plasmid pLNCX (kind gift of Paul Bates), previously engineered to carry a
WPRE.
Viral particle production and infection
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VSV-G pseudotyped HIV vector particles were produced by Lipofectamine
transfection of 293T cells with p156RRLsin-PPTCMVGFPWPRE [35], the
packaging construct pCMVdeltaR9 [36], and the vesicular stomatitis virus Gproducing pMD.G construct. Viral supernatant was harvested 38 hours after
transfection, filtered through 0.22µm filters, concentrated by filtration through a
Centricon, treated with DNase I, and stored frozen at -80°C. HIV titer was quantified
by p24 ELISA.
Cells were infected 48h after transfection: medium from the transfection was
removed and replaced with DMEM + 10% FBS and 50µg/ml gentamycin containing
50-100ng p24 VSV-G pseudotyped virus. Infection mix was left on the cells
overnight and then replaced with fresh medium. Infection was allowed to proceed for
48h, after which cells were trypsinized and harvested for FACS, proviral Q-PCR,
gene expression analysis by Q-RT-PCR, or integration site analysis.
Q-PCR
For quantification of integrated proviruses, a two-step Alu-PCR assay was
used, described in reference [37]. This consists of an intitial round of amplification
from genomic Alu repeats to viral Gag sequence, followed by Q-PCR specific for an
amplicon in R-U5 with molecular beacon probes on an Applied Biosystems 7500 Fast
Realtime PCR instrument. Samples were run in triplicate.
For gene expression analysis, total RNA was extracted from cells using the
Illustra RNAspin kit (GE healthcare). 50ng RNA from each sample was reverse
transcribed using the High Capacity RNA to cDNA kit (Applied Biosystems). cDNA

149

was diluted 100-fold and QPCR performed in triplicate on each sample with
commercial primers and Taqman MGB FAM-labeled probes (Applied Biosystems,
SETD2 assay ID: Hs00383438_m1) and Taqman Fast Universal Mastermix (Applied
Biosystems, catalog number 4352042). Q-PCR was also performed on all samples
with GAPDH primers and probe (Applied Biosystems catalog number: 402869).
SETD2 expression was calculated by the ΔΔCt method. An Applied Biosystems
7500 Fast Realtime PCR instrument was used.
Western blot
Cell pellets were lysed in 1X RIPA buffer with protease inhibitors (Roche,
catalog number 11697498001), lysates mixed with SDS buffer and subjected to SDS
polyacrylamide gel electrophoresis. Flag was detected using anti-Flag M2-peroxidase
conjugated (Sigma, catalog number A8592). β-tubulin was used as a loading control
(Abcam ab21058). SETD2 detection with Abcam antibody ab69836 was attempted
but gave only non-specific bands. Visualization was by chemiluminesence, using
Supersignal West Chemiluminescent substrate (Pierce, catalog number PI34080).
Integration site analysis
Integration sites were isolated and sequenced by ligation-mediated PCR
essentially as described previously [38]. Genomic DNA was extracted from infected
cells using the Qiagen DNeasy tissue extraction kit. Up to 2µg of DNA from each
infection was digested overnight using MseI. This was followed by digestion to
prevent amplification of internal viral fragments (from the 5’ LTR) and plasmid
backbone with SacI and DpnI. Linkers were then ligated onto digested products
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(oligonucleotide sequences listed below) and nested PCR performed from ligation
products. Nested PCR primers contained 8 nt barcode sequences between the
sequencing primer and LTR-binding portions. These enabled pooling of all PCR
products into one sequencing reaction and subsequent separation of sequences by
decoding the barcodes. Samples were sequenced on the Roche 454 GS-FLX
instrument at the University of Pennsylvania.
Integration sites were judged to be authentic if the sequences had a best unique
hit when aligned to the murine (mm8 draft) using BLAT, and the alignment began
within 3bp of the viral LTR end and had >98% sequence identity. Detailed statistical
methods are described in [6].
To control for possible biases in isolating integration sites due to restriction
enzyme sequence distribution, three or ten matched random controls were
computationally generated for each experimental integration site that were the same
distance from the closest MseI restriction site as the experimental site.
Integration site counts in various genomic annotations were compared with
matched random controls by the Fisher’s exact test. Additionally, multiple regression
models for integration intensity were applied, as described in [6]. Analysis was
carried out in the R statistical package (http://www.r-project.org).
5.4 Results
HIV infection is inhibited by knockdown of MAP4, PRPF38A and SETD2
König and colleagues recently conducted a genome-wide siRNA screen to
identify human genes necessary for HIV infection [27]. 293T cells were treated with
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siRNAs against a panel of around 20,000 genes and hits identified as genes that, when
knocked down by two or more independent siRNAs, led to a block in HIV reporter
gene expression. Hits were prioritized for downstream analysis based on several lines
of evidence such as cellular toxicity of knockdown, co-expression with CD4, CXCR4
and CCR5, and evidence of interaction with HIV proteins. For genes passing these
filters, the infection block induced by siRNA treatment was placed in a stage of the
viral lifecycle. We focused on hits from the screen whose effects had been mapped to
the integration step of the lifecycle. MAP4, a microtubule associated protein, and
PRPF38A, a splicing factor, were two such factors. Additionally, we investigated the
potential role of SETD2/HYPB, a histone methyltransferase suggested to interact
with a LEDGF/p75-binding protein.
293T cells were treated with siRNAs directed against PRPF38A, MAP4,
SETD2 or luciferase as a control, and 48h later infected with VSV-G pseudotyped
GFP-expressing HIV. Cells were harvested 48h later for FACS analysis to measure
infection efficiency, and for integration site analysis. Table 5-1 summarizes the genes
studied and their effects on HIV infection. In agreement with the results of König et
al., knockdown of both MAP4 and PRPF38A caused a decrease in susceptibility to
HIV infection (on average 1.67-fold and 1.35-fold respectively). Knockdown of
SETD2 with two different siRNAs also led to a decrease in HIV infection efficiency
(on average a 1.51-fold decrease in GFP expression).
HIV integration site selection is modified by knockdown of PRPF38A, SETD2 and
MAP4

152

Gene

Information

Known functions siRNA used

Control
(luciferase)
PRPF38A

MAP4

SETD2

Identified in siRNA screen
(integration factor)
Identified in siRNA screen
(integration factor); binds
LEDGF/p75 by Y2H.
Binding partner of IWS1,
which interacts with
LEDGF/p75

Fold Reduction
HIV Infection
(FACS)

GL2

1.00

PRPF38A_2

1.67

PRPF38A_3

nd

Microtubule
binding

MAP4_3

1.20

MAP4_4

1.49

H3K36
methyltransferase

SETD2_1

1.61

SETD2_2

1.40

Spliceosome

Table 5-1. Effects of genes studied on HIV infection efficiency. 293T cells were
transfected with the siRNAs shown 48h prior to infection with VSV-G pseudotyped
GFP-expressing HIV. The percentage of cells expressing GFP was determined by
FACS 48h post-infection. Numbers are expressed as fold reduction of this value
compared with control-infected cells.
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Having confirmed that knockdown of MAP4, PRPF38A and SETD2 reduced
the efficiency of HIV infection, we examined the effect of these potential cofactors on
integration site selection. Integration site amplification was carried out essentially as
described previously [38], sites aligned to the human genome and nearby genomic
features annotated. The number of integration sites analyzed from each siRNA
treatment and summaries of genomic features near these sites are shown in Table 5-2.
For reference, a dataset from 293Ts stably knocked down for LEDGF/p75 (the siLL
cells from [24]) is shown, as well as a set of computationally generated random
controls (see methods). One of the goals of this study was to identify factors that may
participate in LEDGF/p75 tethering. Depletion of factors that cooperate with
LEDGF/p75 would be expected to alter integration targeting in the same way as
LEDGF/p75 depletion does. We therefore started by examining the preference for
integration in genes. Table 5-2 summarizes the proportions of integration sites falling
in transcription units from cells treated with various siRNAs. Consistent with
previous data, HIV integration from control cells was favored in the bodies of
transcription units, with 72.1% of sites falling in RefSeq genes.[12], and this
preference was reduced in LEDGF/p75 knockdown cells [24]. Integration sites from
cells treated with siRNAs against MAP4, PRPF38A and SETD2 all showed slight
decreases in the frequency of integration in transcription units, with MAP4
knockdown showing the weakest effect (67.6% and 65.7% in genes depending on the
siRNA used), PRPF38A intermediate (61.8% and 62.7% in genes) and SETD2 the
strongest effect (59.5% in genes). Comparing these proportions to those in control
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Data set

Integration
sites

% in
genes

GL2
PRPF38A_2
PRPF38A_3
MAP4_3
MAP4_4
SETD2_1
LEDGF_siLL
Random

4152
1591
721
3730
3418
2271
468
12954

72.1
61.8***
62.7**
67.6
65.7**
59.5***
59.2***
35.6***

Average
Average
GC % in number genes in
5kb
1Mb
40.5
38.0***
38.7***
39.4***
39.9***
39.1***
41.8***
39.7***

20.2
13.8***
15.1***
17.5***
17.9***
17.0***
18.9
10.1***

Table 5-2. Effect of cofactor knockdown on the genomic distribution of HIV
integration sites. Cells were transfected with the siRNAs shown and 48h later
infected with VSV-G pseudotyped HIV. Integration sites were isolated 48h postinfection, aligned onto the genome and annotated with respect to the genomic features
shown. Asterisks denote statistical significance as determined by a c-logit test
applied to a logistic regression model, or Mann-Whitney U test as appropriate.
* p<0.05, ** p<0.01, ***p<0.0001.
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cells achieved statistical significance, but as shown in Table 5-2, the changes were of
smaller magnitude than those seen in LEDGF/p75-depleted cells. It should also be
noted that the LEDGF/p75 knockdown shown here is a partial knockdown – more
stringently depleted models have been made in other cell types that show a greater
reduction in the frequency of integration in genes (see Chapter 2).
Another effect observed in LEDGF/p75-depleted cells is a shift of integration
sites into regions of higher GC content [22-24]. We therefore wondered whether
knockdown of these factors might show the same effect, supporting the idea that these
factors are part of the LEDGF/p75 machinery. Table 5-2 shows the average GC
content of 5kb regions surrounding integration sites isolated from control and siRNAtreated cells. It can be seen that the GC content of regions surrounding integration
sites from different treatments varied, with LEDGF/p75 knockdown showing an
increase in GC content as previously reported. However all other knockdowns
showed decreases in the average GC content. While these differences did achieve
statistical significance when compared to control cells, the magnitude of the changes
was very small (ranging from 41.8% GC in LEDGF/p75 knockdown cells to 38.0% in
PRPF38A knockdown cells). A more sensitive way to analyze this type of data than
to examine the average value surrounding each site is to compare the distributions of
values around sites from two conditions. Since siRNAs targeted against the same
gene showed similar effects, we pooled integration sites from different siRNAs to
generate such graphs. Figure 5-1 shows this analysis. The GC content in the 5kb
surrounding each integration site was calculated, then sites from control and treated
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Figure 5-1. The effect of cofactor knockdown on integration with respect to GC
content. HIV vector integration sites from cells treated with siRNAs against each
of the genes shown were isolated and mapped onto the genome. The GC content in
a 5kb window around each site was calculated. Sites from control and knockdown
sets were combined and split into ten bins of increasing GC content with equal
numbers of sites in each bin. The proportion of each set found in each bin is shown.
P values were determined using the likelihood ratio statistic for the logistic regression model. LEDGF/p75 knockdown data are from stable knockdown 293T cells as
in [19].
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cells combined and broken into ten bins of increasing GC content. The proportion of
sites from each treatment found in each bin is displayed. It can be seen that, whereas
LEDGF/p75 depletion led to an increase in the GC content around sites, knockdown
of PRPF38A, SETD2 and, to a lesser extent, MAP4, had the opposite effect. Though
these changes are all slight, they are statistically significant, and the difference
between LEDGF/p75 knockdown and the other knockdowns argues against the idea
that knockdown of the genes studied here disrupts the same complex as LEDGF/p75
depletion.
A number of genomic features tend to correlate in the genome, for example
regions with a high GC content tend to also be gene-rich. We therefore analyzed the
gene density of 1Mb windows surrounding integration sites from cells treated with
different siRNAs. The results are summarized in Table 5-2 and shown graphically in
Figure 5-2, analyzed in the same way as GC content in Figure 5-1. In agreement with
the effect on GC content, we observed that knockdown of PRPF38A, SETD2 and
MAP4 led to integration sites lying in less gene-dense regions. LEDGF/p75
knockdown, however, had no effect on gene density surrounding integration sites,
again arguing against the idea that any of the novel factors tested here participate in
LEDGF/p75-mediated integration tethering.
The effects of SETD2 knockdown may be off-target
siRNA treatment is known to cause off-target effects, such as knockdown of
additional genes with sequence similarity to the target gene, or induction of an
interferon response [39]. Using two siRNAs targeted against each gene increased our
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Figure 5-2. The effect of cofactor knockdown on integration with respect to
gene density. HIV vector integration sites from cells treated with siRNAs against
each of the genes shown were isolated and mapped onto the genome. The number
of RefSeq genes in a 1Mb window around each site was calculated. Sites from
control and knockdown sets were combined and split into ten bins of increasing
gene density with equal numbers of sites in each bin. The proportion of each set
found in each bin is shown. P values were determined using the likelihood ratio
statistic for the logistic regression model. LEDGF/p75 knockdown data are from
stable knockdown 293T cells as in [19].

159

109

confidence that the effects on infection and integration site selection were
authentically due to depletion of the proteins of interest. However, we sought to
confirm the specificity of the effect by delivering to knockdown cells an siRNAresistant clone of the gene of interest, and testing for the block to infection. This
allows expression of the protein to be rescued, but any potential off-target effects
induced by the siRNA treatment to remain.
cDNAs of SETD2 were engineered to contain 7 synonymous mutations in the
21bp recognition sequences of the two siRNAs that inhibited HIV infection. These
mutated cDNAs were flag-tagged for ease of detection and cloned into a mammalian
expression vector containing a CMV promoter. 293T cells were cotransfected with
control or SETD2 siRNAs and the rescue constructs, or empty vector as a control.
48h later, cells were infected as before, and 48h after infection cells were harvested.
SETD2 transcription was measured by quantitative RT-PCR and expression of the
flag-tagged rescue constructs was measured by Western blot. Figure 5-3A and B
shows that the rescue constructs were successfully expressed at the level of RNA and
protein. The susceptibility of cells to HIV infection was determined by measuring
integrated viral copies by quantitative PCR. These results are displayed in Figure 53C. Cells transfected with the control siRNA and rescue constructs showed slight
increases in infection efficiency compared with control cells, indicating that
overexpression of SETD2 was not toxic or inhibitory to infection. Cells treated with
the two siRNAs directed against SETD2 showed a roughly 3-fold reduction in the
number of integrated proviruses. Cotransfection of rescue constructs did not lift this

160

1000
100
10

G
veemL2 +
c t pt y
or
re GL
sc 2
ue +
1
re GL
sc 2
ue +
2
s
veemi 1 +
c t pt y
or
re si 1
sc +
ue
1
s
veemi 2 +
c t pt y
or
re si 2
sc +
ue
2

1
0.1

G
veemL2 +
c t pt y
or
re GL
sc 2
ue +
re GL 1
sc 2
ue +
si 2
e
ve m 1 +
c t pt y
o
re si 1r
sc +
ue
1
s
veemi 2 +
c t pt y
or
re si 2
sc +
ue
2

B

SETD2 RNA expression,
relative to GL2 + empty vector

A

Flag

2.5
2
1.5
1
0.5
0

G
veemL2 +
ct pty
or
re GL
sc 2
ue +
1
re GL
sc 2
ue +
2
s
veemi 1 +
ct pty
or
re si 1
sc +
ue
1
s
veemi 2 +
ct pty
or
re si 2
sc +
ue
2

C

Integrated HIV proviruses,
relative to GL2 + empty vector

β−tubulin

Figure 5-3. The infection block induced by SETD2 siRNA treatment is not
rescued by overexpression of siRNA-resistant SETD2 cDNA. A. Expression of
SETD2 RNA, measured by Q-RT-PCR. Values shown are means of two biological
replicates, plus and minus standard deviation. B. Representative Western blot for
Flag-tagged construct expression. C. Integrated HIV proviruses, measured by Q-PCR.
Values shown are means of two biological replicates, plus standard deviation.
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infection block. It remains possible that the Flag-tagged constructs used here were
misfolded, Myc- and Flag-tagged SETD2 or portions of SETD2 have been used with
apparent success in previous publications [40]. This result therefore fails to rule out
the possibility that off-target effects are responsible for the inhibition of HIV
infection by SETD2 knockdown.
Knockdown of other genes involved in HIV integration and nuclear import shows
similar results
Experiments conducted by Troy Brady and Karen Ocwieja in the lab (data not
shown) have examined the effect of other knockdowns on HIV integration site
selection. Two more hits were selected from genes identified in the König siRNA
screen. ANAPC2 is another gene identified in the screen as a factor that when
knocked down reduced the level of HIV integration. It is a component of the
anaphase promoting complex involved in cell cycle regulation [41]. TNPO3
(transportin SR2) is a member of the karyopherin β family of proteins that shuttles
between the nucleus and cytoplasm and is involved in nuclear import of proteins such
as SR splicing factors [42]. Knockdown of TNPO3 was shown to inhibit HIV
infection at the stage of nuclear import in two recent genome-wide siRNA screens
[27, 31]. It was also independently identified as interacting with HIV integrase [10]
and confirmed to be required for nuclear import, though subsequent studies of its role
in infection have suggested the involvement of the capsid protein [43].
Knockdown of ANAPC2 and TNPO3 in 293T cells, infection and integration
site analysis was conducted as described above for SETD2, PRPF38A and MAP4.
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The effects of knockdown of ANAPC2 and TNPO3 were found to be similar to those
reported here. ANAPC2 and TNPO3 knockdown did not show significant effects on
the frequency of integration within transcription units, but did lead to a reduction in
the GC content and gene density of chromatin surrounding HIV integration sites.
Add-back experiments, as described here for SETD2, were completed for both
TNPO3 and ANAPC2. In those cases, rescuing gene expression did mediate at least a
partial rescue of the infectivity and integration site effect.
5.5 Discussion
Much attention has recently been paid to host factors necessary for HIV
infection. Studying interactions between host and viral proteins is valuable in
furthering our understanding of the HIV lifecycle and identifying potential
therapeutic targets. One aspect of the lifecycle where host factors are known to be
important is integration and the targeting of certain genomic features by integration
events: LEDGF/p75 is required for efficient integration and determining much of the
preference of lentiviruses for integration in transcription units. However, other
factors may also be important, either as part of the LEDGF/p75 machinery, or as a
parallel system still active in its absence.
In this study we investigated whether host proteins whose knockdown inhibits
HIV infection at the step of integration also have an impact on integration site
selection. We tested this by treating cells with siRNAs directed against three factors,
PRPF38A, MAP4 and SETD2 whose knockdown reduced HIV infection efficiency.
Small but statistically significant changes in the genomic distribution of integration
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sites were observed, with broadly similar effects resulting from the three
knockdowns: the frequency of integration in genes was slightly reduced, the GC
content of 5kb windows around integration sites was reduced, and the gene density of
1Mb windows around integration sites was reduced.
The significance of these findings remains unclear. Importantly, the changes
induced by knockdown of these proteins differ from the changes induced by
LEDGF/p75 depletion. This argues against the idea that the factors tested were
LEDGF/p75 cofactors. A number of interpretations could therefore be imagined. The
first is that the proteins studied in this work all assist in the nuclear trafficking of the
pre-integration complex, enabling nuclear import (eg. TNPO3) or integration (eg.
PRPF38A, MAP4, SETD2, ANAPC2). This is known to be true for TNPO3, and
suggested, though not demonstrated, for MAP4 and SETD2, by their purported
interaction with LEDGF/p75 or its binding partners. Disruption of this trafficking
might alter the placement of integration events in chromatin. Chromatin is known to
be organized into higher order structures in the nucleus, with characteristic
distributions of particular genomic regions [44]. Perhaps disruption of nuclear
trafficking pathways, by depletion of any of the above factors, misdirects PICs into
less gene-dense, GC-rich regions of the genome.
However, questions remain about off-target effects. The infection block
induced by SETD2 siRNAs could not be rescued by siRNA-resistant cDNA
expression, and the integration site effects observed in this system were very similar
to those observed in others. Another possible interpretation of the data therefore
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remains: that siRNA treatment resulted in knockdown of some unintended factor or
induced an innate immune or stress response. In this situation, some other indirectly
modulated factor could be the true mediator of integration targeting in gene-dense
regions. Relatedly, such off-target effects could alter cellular chromatin structure to
make gene-dense regions less accessible. The induction of an interferon response
could be studied by assaying the expression of interferon-inducible genes following
siRNA treatment. Similarly, cells could be treated with interferon-β prior to infection
to see if the integration site selection was redistributed as reported here.
A related confounding effect could be that on-target depletion of these
proteins, though not affecting HIV infection directly, results in global gene
expression changes that then alter integration targeting, by modulating some tethering
factor or causing changes in chromatin accessibility.
It should be noted that similar effects to those reported here have been
observed when comparing integration site selection in other settings. Comparing
dividing and growth-arrested IMR90 fibroblasts, Ciuffi et al. [45] found that HIV
integration sites from dividing cells were in less gene-dense regions than growth
arrested cells. This result could lend support to the idea that passage of the PIC
through the nuclear pore, which would be necessary in non-cycling cells, may have
an impact on the distribution of sites in chromatin. However, the opposite effect was
reported by Brady et al., who showed that integration sites in activated T-cells were
in more gene-dense and GC-rich regions than integration sites in resting T-cells,
which divide less [46]. Furthermore, Chapter 6 of this dissertation presents data that
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pharmacological inhibition of integrase strand transfer also leads to similar effects on
HIV integration site selection.
In all, these data suggest that HIV integration targeting may be shaped by
variables in addition to LEDGF/p75 expression. Whether the proteins described here
participate in this process, or their knockdown affected integration in some other way
requires further study.
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CHAPTER 6 – THE EFFECT OF RALTEGRAVIR TREATMENT ON HIV
INTEGRATION SITE SELECTION

6.1 Abstract
HIV shows a preference for integration in transcription units and gene-dense
parts of the genome. This preference is thought to be mediated by interactions of
viral components of the pre-integration complex with host chromatin-bound factors
that act as integration tethers. This has been shown with one host factor,
LEDGF/p75, which interacts with integrase proteins of HIV and other lentiviruses,
and whose depletion impairs integration and alters its genomic distribution. It is
thought that additional factors – either other tethering proteins or passive chromatin
accessibility – also contribute to HIV integration targeting. A recent approach to
identifying novel host factors has been to study factors that, like LEDGF/p75, are
necessary for efficient infection, and determining the effect of their depletion on HIV
integration targeting. We tested the effect on integration targeting of impairing
infection by pharmacological means. Cells were treated with reverse transcriptase
inhibitors AZT or Nevirapine, or the integrase inhibitor Raltegravir. We found that
Raltegravir treatment altered the genomic distribution of integration sites, causing a
shift to less gene-dense and GC-rich parts of the genome. Other inhibitors had no
significant effect. These changes resemble those observed in HIV cofactor
knockdown, leading us to speculate that a similar mechanism may be involved. We
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tested the idea that retargeting was related to a delay in the timing of integration, but
found no conclusive evidence in support of this.
6.2 Introduction
Integration is a necessary step in the lifecycle of retroviruses such as HIV,
enabling the virus to establish life-long infection and form a latent reservoir. The
integration reaction is mediated by the viral enzyme integrase (IN) [1-3]. IN mediates
two reactions: terminal cleavage, whereby the last two nucleotides are removed from
the end of each LTR of the reverse-transcribed genome; and strand transfer, where the
target DNA is nicked once on each stand and the two recessed 3’ hydroxyl groups
exposed by terminal cleavage are inserted in a concerted fashion [4-7]. HIV IN is a
288 amino-acid protein in the RNaseH superfamily, composed of 3 structural
domains. The central catalytic core domain (aa 51-212) contains an RNaseH fold
found in many DNA and RNA modifying enzymes [8, 9]. Three acidic residues, DDX35-E, referred to as the catalytic triad, coordinate two divalent metal ions necessary
for catalysis [10, 11].
As an essential viral enzyme without a cellular counterpart, IN makes a good
target for the development of antiretrovirals. In 2007, the first integrase inhibitor,
Raltegravir, developed by Merck, was approved by the FDA, and has since had great
success in the clinic [12]. Raltegravir belongs to a class of compounds called diketo
acids, thought to function by chelating the metal cations at the IN active site [13, 14].
This class of inhibitors specifically inhibits strand transfer, with much weaker
inhibition of terminal cleavage [13]. It is thought that Raltegravir binds selectively to
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IN in complex with viral DNA, and prevents the complex from binding to target
DNA [15]. Cytoplasmic pre-integration complexes (PICs) from diketo-acid treated
cells showed reduced in vitro strand transfer activity, suggesting that Raltegravir may
bind the IN-viral DNA complex before entry into the nucleus [13, 16].
Integration events are non-randomly distributed in the genome of the infected
cell, with retroviruses showing genus-specific preferences for genomic features [17].
HIV and related lentivruses show a preference for integration in active transcription
units and relatively gene-rich regions [18]. This non-random genomic distribution is
thought to effect optimal viral gene expression – it has been shown that
transcriptionally silent HIV proviruses tend to show more integration in normally
disfavored regions such as gene deserts and centromeric alphoid repeats [19]. The
integration preferences of lentivruses such as HIV have been shown to be mediated
by a chromatin-associated host protein, LEDGF/p75, which interacts with IN,
tethering integration to chromatin, probably within the bodies of transcription units
[20-22]. However, the genomic distribution of lentiviral integration sites in the
absence of LEDGF/p75 is not fully random, suggesting other influences may also be
important. Suggestions of such influences have included effects of the cell cycle
[23], additional tethering factors (discussed in Chapter 5 of this dissertation) and
passive chromatin accessibility [24].
In this chapter, we present data that pharmacological inhibition of HIV
integration by Raltegravir also alters the genomic distribution of integration sites.
293T or Jurkat cells were treated with concentrations of Raltegravir that permitted
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low levels of infection. Analysis of the genomic distribution of resultant integration
sites showed that while IN’s weak sequence specificity was not affected, integration
sites from treated cells were found in less gene-dense and GC-rich regions. This was
not the case when infection was inhibited with reverse transcriptase inhibitors AZT or
Nevirapine, nor when untreated cells were infected at a lower MOI. While the
mechanism of this effect remains unclear, it does not appear to result from a delay in
integration kinetics in the presence of Raltegravir.
These findings are provocative in our developing understanding of the factors
shaping retroviral integration targeting, and also of the effect of this new class of
antiretrovirals on aspects of HIV replication in treated patients.
6.3 Materials and Methods
Cell culture
293T cells were cultured in Dulbecco’s Modified Eagle Medium with
Glutamax (Invitrogen), 10% FBS (Sigma) and 50µg/ml gentamycin (Sigma). Jurkat
cells were cultured in RPMI (Invitrogen), 10% FBS (Sigma) and 50µg/ml gentamycin
(Sigma).
Virion production and infections
VSV-G pseudotyped HIV vector particles were produced by Lipofectamine
transfection of 293T cells with p156RRLsin-PPTCMVGFPWPRE [25], the
packaging construct pCMVdeltaR9 [26], and the vesicular stomatitis virus Gproducing pMD.G construct. Viral supernatant was harvested 38 hours after
transfection, filtered through 0.22µm filters, concentrated by filtration through a
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Centricon, treated with DNase I, and stored frozen at -80°C. HIV titer was quantified
by p24 ELISA.
293T cells were seeded in 12-well plates, 300,000 cells per well, 6-8h before
infection. Jurkat cells were aliquoted into 24-well plates, 500,000 cells per well, at
the time of infection. For ‘high MOI’ infections, 293T cells were infected with 60ng
p24 per well, Jurkats with 100ng p24 per well. For ‘low MOI’ infections, 300,000
293T cells were infected with 20ng p24 per well. The infection medium contained
the appropriate culture medium, virus and DMSO, AZT, Nevirapine or Raltegravir at
the concentrations stated. Each condition was conducted in quadruplicate. Infections
were allowed to proceed overnight, then medium was replaced with fresh medium
containing inhibitor or DMSO as appropriate. Cells treated with AZT and Nevirapine
were harvested 48h after infection. Cells treated with Raltegravir were passaged for 2
weeks after infection to dilute unintegrated viral genomes. Cells treated with DMSO
and infected at lower MOI were harvested after 48h, and cells treated with DMSO
and infected at higher MOI were passaged for 2 weeks before harvesting. When
passaging, inhibitor concentrations used at the time of infection were maintained.
For the time-course experiment, 250,000 293T cells were seeded per well of
12-well plate, seeding 4 wells per time-point. The following morning, cells were
infected with 60ng p24 and 2.5ul DEAE-dextran per well. Each condition was
conducted in quadruplicate. Infection was allowed to proceed for 2hr. The 0h timepoint was harvested immediately after removal of the infection mix. For wells
containing longer time-points, infection mix was removed and replaced with DMEM
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with 10% FBS and 50µg/ml gentamycin containing DMSO or 10nM Raltegravir as
appropriate. The same medium was left on until cells were harvested, at the timepoint stated.
Integration site analysis
Integration sites were isolated and sequenced by ligation-mediated PCR
essentially as described previously [27]. Genomic DNA was extracted from infected
cells using the Qiagen DNeasy tissue extraction kit. Up to 2µg of DNA from each
infection was digested overnight using MseI. This was followed by digestion to
prevent amplification of internal viral fragments (from the 5’ LTR) and plasmid
backbone with SacI and DpnI. Linkers were then ligated onto digested products
(oligonucleotide sequences listed below) and nested PCR performed from ligation
products. Nested PCR primers contained 8 nt barcode sequences between the
sequencing primer and LTR-binding portions. These enabled pooling of all PCR
products into one sequencing reaction and subsequent separation of sequences by
decoding the barcodes. Samples were sequenced on the Roche 454 GS-FLX
instrument at the University of Pennsylvania.
Integration sites were judged to be authentic if the sequences had a best unique
hit when aligned to the murine (mm8 draft) using BLAT, and the alignment began
within 3bp of the viral LTR end and had >98% sequence identity. Detailed statistical
methods are described in [28].
To control for possible biases in isolating integration sites due to restriction
enzyme sequence distribution, three or ten matched random controls were
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computationally generated for each experimental integration site that were the same
distance from the closest MseI restriction site as the experimental site.
Integration site counts in various genomic annotations were compared with
matched random controls by the Fisher’s exact test. Additionally, multiple regression
models for integration intensity were applied, as described in [28]. Analysis was
carried out in the R statistical package (http://www.r-project.org).
Q-PCR for integrated proviruses
A two-step Alu-PCR assay was used, described in reference [29]. This
consists of an intitial round of amplification from genomic Alu repeats to viral Gag
sequence, followed by Q-PCR specific for an amplicon in R-U5 with molecular
beacon probes on an Applied Biosystems 7500 Fast Realtime PCR instrument. Each
sample was run in triplicate. In order to standardize values across QPCR plates,
samples were run on multiple plates as external controls. Values for each plate were
set to these control values.
6.4 Results
Isolation of HIV integration sites
293T or Jurkat cells were infected with a VSV-G pseudotyped GFP-encoding
HIV vector in the presence of Raltegravir or DMSO as a control. As additional
controls, 293T cells were infected in the presence of AZT or Nevirapine, and
infection with DMSO was repeated with a lower virus inoculum. AZT- and
Nevirapine-treated cells were harvested 48 hours after infection. Raltegravir-treated
cells were found to accumulate 2-LTR circles, consistent with Raltegravir function
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[13], which contaminated integration site amplification. These cells were therefore
passaged for 14 days before harvesting. The lower MOI infection was harvested 48h
post-infection, the higher after 2 weeks of passaging. The conditions used are shown
in Table 6-1.
Integration sites were isolated and amplified from genomic DNA essentially
as previously described [30]. The numbers of unique integration sites passing quality
control are shown in Table 6-1. For reference, values for computationally generated
random sites are shown. Random sites were generated that are matched to each
dataset; Table 6-1 shows data from sites matched to the 293T DMSO high MOI
dataset (see Materials and Methods for explanation).
Consensus sequence preference at HIV integration sites is preserved in the presence
of antiretrovirals
Retroviral integrases show weak consensus sequences at the site of
integration, consisting of an inverted repeat that varies between viruses [28, 31-35].
This consensus is a property of the integrase protein, with the symmetry of the
inverted repeat thought to arise from IN binding as a dimer. In the case of HIV IN,
the consensus is TDG↓GTWACCHA, where the arrow represents the site of
integration [32, 35]. We therefore verified that in the presence of antiretrovirals, the
target sequence preference of IN was not affected. Figure 6-1 shows that target site
consensus sequences from the different treatments did not vary and were consistent
with the published sequence. This indicates that the integration sites isolated were
bona fide integration events, catalyzed by HIV IN.
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Data set
293T DMSO high MOI
293T DMSO low MOI
293T AZT 300nM
293T Nevirapine 100nM
293T Nevirapine 300nM
293T Raltegravir 10nM
293T Raltegravir 25nM
Jurkat DMSO
Jukat Raltegravir 5nM
Jurkat Raltegravir 10nM
Jurkat Raltegravir 100nM
Random

% GFP
positive
(FACS)
89.6
40.9
25.5
11.5
24.1
31.5
13.2
98.6
42.3
36.3
20.3

Integration
sites

% in
genes

871
300
293
415
114
316
68
1890
1225
1218
683
5670

72.4
73.7
71.7
71.6
78.9
74.7
73.5
73.8
75.4
76.0
73.9
35.7***

Average
number genes
in 1Mb
20.7
20.0
18.8
22.0
18.2
17.4**
16.9*
19.6
15.8***
15.2***
14.3***
9.95***

Average
GC % in
1Mb
43.7
43.5
42.9
44.3
43.5
42.4**
42.2*
43.5
41.7***
41.4***
41.0***
40.3

Table 6-1. Integration sets generated in this study and their genomic
distributions. Cells were infected under the conditions shown. ‘Random’ is a set of
computationally generated random sites in the genome, matched to the ‘DMSO high
MOI’ set in terms of the distance of each site to the nearest MseI restriction site (see
Methods for details). Asterisks denote statistical significance by the Fisher’s exact
test or Mann-Whitney U test as appropriate in the comparison with 293T DMSO high
(for 293T sets) or Jurkat DMSO (for Jurkat sets). * p<0.05, ** p<0.01, ***p<0.0001.
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Figure 6-1. HIV integrase consensus sequence is not affected by antiretroviral
treatment. The 20bp sequences immediately surrounding integration sites from each
treatment were aligned to generate a consensus using the Weblogo program
(weblogo.berkeley.edu). The x-axis represents the base position relative to the site of
integration (between position -1 and 0). The y-axis represents the bits of information
contained at each position (the maximal value, if a position only ever had one of the 4
bases, would be 2 bits).
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3’

HIV integration site selection is altered by Raltegravir treatment
HIV integration normally favors the bodies of active transcription units, and
regions of the genome with a high gene density [18]. We therefore started by
examining the correlation of integration sites with these features. Table 6-1
summarizes the proportions of integration sites in each treatment falling within
transcription units annotated by the RefSeq gene call. It can be seen that, consistent
with published data, HIV integration is roughly two-fold enriched in transcription
units over random. No statistically significant differences were observed between
cell types, MOIs or antiretroviral treatments.
We next examined the correlation between integration frequency and gene
density. The average number of genes within a 1Mb window around sites from each
treatment is shown in Table 6-1. It can be seen that sites from cells infected at
different MOIs did not differ in the gene density of the surrounding DNA. Reverse
transcriptase inhibitors AZT and Nevirapine also had no effect on the gene density
surrounding HIV integration sites. However, Raltegravir treatment caused a small
but statistically significant drop in the average gene density in a 1Mb window around
HIV integration sites, an effect which was reproduced in both 293T and Jurkat cell
lines: in 293T cells, sites from control cells had on average 20.7 genes in the
surrounding 1Mb, which was reduced to 17.4 an 16.9 in 10nM and 25nM Raltegravir;
sites from Jurkat cells similarly dropped from 19.6 genes per Mb to 15.8 and 15.2 at
5nM and 10nM respectively. Since, based on Table 6-1, it appeared that different
dosages of each antiretroviral showed the same trend, sites were pooled across
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concentrations in subsequent analysis. Figure 6-2 shows pairwise comparisons of the
correlation between integration frequency and gene density in control and drugtreated cells. These graphs were made by combining the two datasets to be
compared, binning sites into 10 bins of increasing gene density with equal numbers of
sites in each bin, and plotting the proportion of each dataset falling within that bin
(described in detail in reference [28]). This enables a sensitive analysis of differences
between sets. This analysis confirmed that the distribution of integration sites from
cells infected at different MOIs or in the presence of RT inhibitors AZT or
Nevirapine did not differ significantly from sites from control infections. However,
integration sites from Raltegravir-treated cells were more commonly found in bins of
lower gene density than sites from control cells. The effect was more pronounced in
Jurkat cells, though these sets also contained more integration sites than those from
293T cells.
A number of genomic features correlate in the genome, for example gene-rich
regions also tend to have short genes, short introns and be high in GC content. We
therefore also examined the relationship between integration frequency and GC
content within a 1Mb window around each site. The effects on GC content are shown
in Table 6-1, and were similar to those for gene density. While DMSO treatment,
MOI and RT inhibition had no effect on the average GC content surrounding
integration sites, regions around sites from Raltegravir-treated cells showed a small
but statistically significant and reproducible drop in GC content (in 293Ts from
43.7% to 42.4% or 42.2%, in Jurkats from 43.5% to 417% or 41.4%). Sensitive
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Figure 6-2. The effect of antiretroviral treatment on integration with respect to gene
density. HIV vector integration sites from cells subjected to each of the treatments shown
were isolated and mapped onto the genome. The number of Refseq genes in a 1Mb window
around each site was calculated. Sites from control and treated sets were combined and split
into ten bins of increasing gene density with equal numbers of sites in each bin. The proportion of each set found in each bin is shown. P values were determined using the likelihood
ratio statistic for the logistic regression model. ‘DMSO’ in 293T panels refers to high MOI
infection of DMSO-treated cells.
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graphical pairwise comparisons between sets are shown in Figure 6-3. A shift can be
seen in the distribution of sites to regions of lower GC content following Raltegravir
treatment in both cell types.
Raltegravir does not influence the kinetics of HIV integration in the cell
We were surprised by the effects of Raltegravir treatment on integration site
selection, since prevalent models of integration targeting have incorporated host
tethering factors and variation in chromatin accessibility [24, 36], which we would
not expect to be affected by Raltegravir. We wondered if the observed effect could
be explained by a kinetic effect on integration – that partial inhibition of Raltegravir
as was performed in this experiment might act to alter the timing of successful
integration events, and thus alter the time available for the unintegrated PIC to traffic
through the nucleus. It is known that chromatin folds into higher order structures in
the nucleus, with particular genomic features clustering in particular places [37]. It
could be imagined that the PIC might need to travel through the nucleus to its final
site of integration, and that the time available to complete this journey could affect
the destination reached. We expected that Raltegravir treatment might slow the
integration reaction, lengthening the time of PIC nuclear trafficking.
To establish whether integration was slowed by Raltegravir treatment, we
conducted a time-course of infection with and without Raltegravir and measured by
quantitative PCR integrated proviral copies at intervals following infection. 293T
cells were infected for 2 hours with VSV-G pseudotyped virus in the presence of
10nM Raltegravir or DMSO as control. Virus was then removed and replaced with
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Figure 6-3. The effect of antiretroviral treatment on integration with respect to GC
content. HIV vector integration sites from cells subjected to each of the treatments shown
were isolated and mapped onto the genome. The GC content in a 1Mb window around each
site was calculated. Sites from control and treated sets were combined and split into ten bins
of increasing gene density with equal numbers of sites in each bin. The proportion of each
set found in each bin is shown. P values were determined using the likelihood ratio statistic
for the logistic regression model. ‘DMSO’ in 293T panels refers to high MOI infection of
DMSO-treated cells.
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medium containing 10nM Raltegravir or DMSO as appropriate for the remainder of
the time-course. Cells were harvested at intervals over the next 72 hours and an Alurepeat-based quantitative PCR assay performed to quantify integrated proviruses.
The results are shown in Figure 6-4. It can be seen that starting around 6h postinfection, the number of proviruses started to increase in both control and treated
cells. In both conditions, the level of integrated proviruses increased until a plateau
was reached. Treatment with Raltegravir reduced this plateau, as expected. As an
indication of the timing of integration in each condition, we calculated the time taken
to synthesize half of the maximal quantity of proviruses for each condition (t1/2max).
Based on this analysis, integration had reached half its maximal value at 16.9h in
control cells and 13.9h in Raltegravir-treated cells. Further repetitions of the
experiment and more time-points between 12h and 24h would be required to establish
whether there was any statistically significant difference between the two treatments,
though these results do not suggest any large effects, and certainly provide no
evidence for retardation of integration.
6.5 Discussion
HIV integration events are distributed in the host genome with characteristic
preferences for transcription units and gene-dense regions. It is known that
LEDGF/p75 contributes to this distribution, but it is possible that other factors play a
role. Here we present data that pharmacological inhibition of HIV integrase by
Raltegravir leads to a redistribution of integration sites into less gene-dense and GCrich regions. The changes were modest but significant and reproducible in both
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Figure 6-4. The effect of Raltegravir treatment on HIV integration kinetics. 293T
cells were infected with HIV in the presence of DMSO or 10nM Raltegravir as shown.
Cells were harvested at intervals after infection and the number of integrated proviruses
quantified by Q-PCR.
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293Ts and Jurkats, and absent in sites from infection at a lower MOI or inhibited at
reverse transcription. In trying to explain this observation, we investigated one
possible explanation – that partial inhibition with Raltegravir altered the timing of
integration and that alterations in PIC nuclear trafficking time might affect the final
location of integration. A preliminary experiment did not provide strong evidence in
favor of this hypothesis, though it suggested that in treated cells successful integration
events, if different, take place earlier. Further experiments with time-points at shorter
intervals would be required to reach a definitive conclusion. If timing were
reproducibly altered by Raltegravir treatment, it could be interesting to analyze the
distribution of integration sites at various times after infection to see if certain sites
were earlier targets.
Another possibility is that Raltegravir induces cellular cytotoxicity, which
leads to either changes in expression of host integration site determinants or global
changes in chromatin structure that influence its accessibility to the PIC. This
possibility could be ruled out by analyzing integration sites from cells infected with
Raltegravir-resistant virus in the presence and absence of drug, analogous to siRNAresistant expression commonly employed in siRNA experiments, as described in
Chapter 5.
Finally, it has recently been found that type I interferons can be induced by
cytoplasmic DNA through a TLR-independent mechanism named the Interferonstimulatory DNA (ISD) response [38, 39]. It has been suggested that cDNA from
reverse transcription of retroviruses and endogenous retroelements may activate the
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ISD response [40-42]. Perhaps inhibition of viral integration by Raltegravir and the
resultant accumulation of viral cDNA and 2-LTR circles induces an innate immune
response such as the ISD that leads to changes in gene expression or chromatin
structure that affect integration site distribution. However, whether the ISD response
is inducible by retroviral infection in the 293T and Jurkat cell lines employed here is
unclear [39]. A potential experiment to test this idea would be to monitor the
expression of interferon-inducible genes in cells treated with Raltegravir.
Additionally, cells could be treated with interferon-β and integration sites analyzed
for recapitulation of the effects observed here. The similarity between the effects of
Raltegravir and the effects of siRNA treatment described in Chapter 5 are striking,
and suggestive of some common underlying mechanism. Perhaps induction of an
interferon response, either in response to the accumulation of viral replication
intermediates through the ISD, or in response to siRNA treatment, causes chromatin
or gene expression changes that result in the effects documented here and in the
preceding chapter.
The mechanism of the observations described here therefore remains unclear.
However, it is of interest that an antiretroviral drug in clinical use appears to alter the
genomic distribution of HIV integration sites. An important question would be
whether these changes have any effect on HIV replication. Lewinski et al. [19]
reported that the positioning of proviruses bears on their transcriptional activity:
transcriptionally silent proviruses were more often found in gene deserts and
centromeric repeats. Therefore, one question would be whether the alteration of
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integration sites by Raltegravir treatment contributes to its antiviral role by impairing
proviral expression.
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CHAPTER 7 – CONCLUSIONS AND FUTURE DIRECTIONS

In this dissertation, I presented studies of the determinants and consequences
of lentiviral integration in human and murine cells. Lentiviruses have evolved to
preferentially integrate into transcription units and gene-dense regions in the genome.
In Chapter 2 of this dissertation, I showed that much of this preference is determined
by an interaction between the viral integrase protein and a host chromatin-associated
protein, LEDGF/p75. I also reported that this preference could be modulated by
variation in LEDGF/p75 expression within the biological range found in different cell
types. However, integration was still not fully random in the absence of LEDGF/p75,
with certain preferences unaffected and new preferences emerging, suggesting other
factors in addition to LEDGF/p75 may be involved.
In Chapter 3 I presented data from cells expressing LEDGF/p75 fusion
proteins with alternative chromatin-binding domains. I reported that a LEDGF/p75
fusion with the heterochromatin-binding protein CBX1 could retarget integration into
normally disfavored sites: intergenic and pericentromeric regions, rich in marks of
transcriptional repression. This argues that, while other factors may play a role in
targeting integration to transcriptionally active genomic regions, LEDGF/p75
tethering appears to be central to targeting, and able to overcome potential barriers to
integration in regions such as pericentric heterochromatin.
Candidate factors that may contribute to lentiviral targeting in addition to
LEDGF/p75 were investigated in Chapters 5 and 6. These studies revealed that
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knockdown of a number of cellular factors, or the induction of other changes to the
cellular or nuclear environment, alter integration site selection. The mechanism
remains unknown, but it appears that these effects differ from the effects of
LEDGF/p75 depletion.
Clarifying the mechanism of the effects observed in Chapters 5 and 6 remains
a goal of future experiments, for example by testing the idea that an innate immune
response was elicited by the experimental conditions used. Analyzing integration
sites in cells knocked down both for LEDGF/p75 and for the factors described in
Chapter 5, or treating LEDGF/p75 knockdown cells with Raltegravir as in Chapter 6,
would also be useful. Preliminary data from such an experiment suggest the effects
described in Chapters 5 and 6 and the effects of LEDGF/p75 depletion described in
Chapter 2 are indeed independent, and additive rather than epistatic (KR, data not
shown). Additionally, mutants of HIV that escape restriction by the host factors
TNPO3 and RANBP2 have been selected (Vineet KewalRamani, Greg Towers,
personal communications). Integration site analysis with these viruses could be
studied to test the proposed connection between the nuclear import pathway and
integration targeting.
One important question arising from these studies concerns the implication of
alterations in integration targeting for viral gene expression. It has been suggested
that the lentiviral preference for integration in expressed genes maximizes proviral
expression, and that integration into unfavorable genomic regions such as gene
deserts impairs proviral expression, potentially contributing to latency [1, 2]. The
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apparently efficient expression of vectors retargeted to heterochromatin in Chapter 3
is therefore surprising. In the future, epigenetic modifications of the integrated
proviral DNA could be studied. The expression of reporter genes from vectors
containing different promoters could also be measured, to address the possibility of
promoter-specific effects. A complication in the experimental system used in Chapter
3 is the stable expression of the CBX1-LEDGF325-530 fusion. It is possible that this
protein interferes with the silencing mediated by endogenous CBX1 recruitment. The
development of a system in which the fusion protein was only transiently expressed
during integration, and subsequently switched off, would help test this idea – perhaps
in the absence of the fusion protein proviral expression would be silenced as
predicted. Another potentially interesting experiment would be to compare the
integration site distributions of well and poorly expressed proviruses following
integration in the presence of the CBX1 fusion, as was performed in reference [1].
This could enable us to ask more carefully if retargeted integration events lead to
reduced proviral expression.
The study of integration retargeting presented in Chapter 3 also has
implications for the use of lentiviral vectors in gene therapy. Previous instances of
retroviral vector-mediated insertional activation and oncogenesis have led to concerns
about the effect of integration in or near genes. The retargeting presented in Chapter
3 suggests that host integration cofactors could be manipulated to direct integration to
parts of the genome considered to be ‘safe’.
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Whether natural patterns of lentiviral integration are a threat to vector safety is
an issue addressed in Chapter 4. Here we analyzed the distribution of integration
sites in mice treated for β-thalassemia with a lentiviral vector. We analyzed bone
marrow after long-term reconstitution, asking if the distribution of integration sites
showed evidence of growth stimulation by vector integration near genes involved in
growth control. In contrast to a previous study in one human patient with the same
vector (Cavazzana-Calvo et al. submitted), but in agreement with studies with other
lentiviral vectors [3, 4], we found no evidence suggestive of insertional activation.
However, we did observe that integration sites in cells having undergone long-term
growth in vivo, or short-term culture ex vivo, were less frequently in transcription
units. This is suggestive of negative selection against cells with proviruses in genes,
as is seen with endogenous retroviruses [5-7]. Given the natural history of HIV
infection, it is perhaps not surprising that integration of an HIV-based vector could
place cells at a selective disadvantage – HIV-infected lymphocytes typically live a
short time after infection [8] so there would be little pressure for HIV to evolve a
benign integration pattern, as is seen in the yeast Ty retrotransposons for example [911].
Considering the findings of Chapters 3 and 4, one wonders where in the
genome is a ‘safe’ integration site. Further analysis of the effect of lentiviral
integration on host gene expression is warranted. Previous studies have shown that
lentiviral integration can lead to both up- and down-regulation of nearby genes [12].
Do certain integration site distributions minimize the deregulation of host gene
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expression? Transcriptional profiling of cells with different integration patterns could
be conducted. LEDGF/p75 fusions present an attractive model in which the
integration preference of a lentiviral vector can be modified and effects on host gene
expression compared. Again, the current LEDGF/p75 fusion protein system
generated in Chapter 3 is complicated by the other modifications of the cells, but
refining the model could enable side-by side comparison.
The studies described in this dissertation contribute to our understanding of
lentiviral integration, its determinants and some of its consequences. They help
illuminate virus-host interactions, aiding in the identification of therapeutic targets,
and contribute to the ongoing development and evaluation of the use of lentiviral
vectors in gene therapy.
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Supplementary Table S4-1. Capture-recapture-based total population estimates
enzyme 1
seen
unseen

enzyme 2
seen
unseen estimate m22=(m12.m21)/m11
m11
m12
m21
m22

MOUSE 31
mouse 31 uncultured
Mse
yes
no

Nla
yes

mouse 31 methylcellulose
Mse
yes
no

Nla
yes

mouse 31 all unique
Mse
yes
no

Nla
yes

no
10
20
8 m22
18

estimate m22
30

no
0
2
3 m22
no
10
22
8 m22
18

estimate total
16

54

no overlap, can't estimate

estimate m22
32

estimate total
17.6

57.6

NOTE: 3/5 sites after methylcellulose are also found before culture
MOUSE 32
mouse 32 uncultured
Mse
yes
no

Nla
yes

mouse 32 methylcellulose
Mse
yes
no

Nla
yes

mouse 32 all unique
Mse
yes
no

Nla
yes

no
6
12
10 m22
16
no
3
3
1 m22
4
no
6
12
10 m22
16

estimate m22
19

estimate m22
6

200

48

estimate total
1

estimate m22
19

NOTE: all 7 sites after methylcellulose are also found before culture
MOUSE 33.1

estimate total
20

8

estimate total
20

48

mouse 33.1 uncultured
Mse
yes
no

Nla
yes

mouse 33.1 methylcellulose
Mse
yes
no

Nla
yes

mouse 33.1 methylcellulose
Mse
yes
no

Nla
yes

no
9
16
9 m22
18
no
4
4
11 m22
15
no
9
18
16 m22
25

estimate m22
25

estimate total
16

estimate m22
8

50

estimate total
11

estimate m22
27

30

estimate total
32

75

12/19 sites after MC are also found before culture
MOUSE 33.2
mouse 33.2 uncultured
Mse
yes
no

Nla
yes

mouse 33.2 methylcellulose
Mse
yes
no

Nla
yes

mouse 33.2 all unique
Mse
yes
no

Nla
yes

no
4
8
13 m22
17
no
1
1
41 m22
42
no
4
7
47 m22
51

estimate m22
12

estimate total
26

estimate m22
2

estimate total
41

84

82.25

estimate total
140.25

estimate m22
11

51

NOTE: 9/43 sites after MC are also found before culture
MOUSE 34
mouse 34 uncultured
Mse
yes
no

Nla
yes

no
7
21
4 m22
11
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estimate m22
28

estimate total
12

44

mouse 34 methylcellulose
Mse
yes
no

Nla
yes

mouse 34 all unique
Mse
yes
no

Nla
yes

no
4
1
3 m22
7
no
7
21
5 m22
12

NOTE: 7/8 sites after MC are also found before culture
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estimate m22
5

estimate total
0.75

estimate m22
28

8.75

estimate total
15

48
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